3 Pharma Stocks With Especially Juicy Dividends

Motley Fool2022-01-17

Key PointsAbbVie is a Dividend Aristocrat that also performed quite well over the past year.Gilead Sciences has increased its dividend 51% over the last five years and should keep the streak going in ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

229

Report

Comment（16）

superpopo
·2022-01-18
Apple juice?
Reply
Like
Report
time to eat
·2022-01-18
Just buy
Reply
Like
Report
Gladys8jk
·2022-01-18
Ok
Reply
1
Report
Samuel123win
·2022-01-18
Wow
Reply
1
Report
Piret
·2022-01-18
Okay
Reply
1
Report
BKT
·2022-01-17
Good. Pls like thanks.
Reply
1
Report
Mengi
·2022-01-17
Nice
Reply
Like
Report
SK19
·2022-01-17
AbbVie 💪💪💪
Reply
Like
Report
Svkartik
·2022-01-17
Juicy only for US residentsFor us, we clearly lose by paying 30% dividend withholding taxes - this is is something most investors turn a blind eye to buy over time it will significantly eat into total shareholder returns US dividend stocks are for trading and not great for Long term for non US residents
Reply
2
Report
LCare Trader
·2022-01-17
Super liked
Reply
4
Report
HoSeyLiao48
·2022-01-17
[Allin] [USD] [Call] [Like]
Reply
4
Report
RetiredPig83
·2022-01-17
Like 👍
Reply
4
Report
aden53
·2022-01-17
Like
Reply
6
Report
lanangqupu
·2022-01-17
New Opportunity for us..good idea
Reply
3
Report
AnaiAnai
·2022-01-17
mostly small player not viable yet.
Reply
6
Report
TradeMore
·2022-01-17
Ok
Reply
4
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1103076176?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-01-17 15:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1103076176","market":"us","top_or_hot":-1,"title":"3 Pharma Stocks With Especially Juicy Dividends","media":"Motley Fool","content":"<div>\n<p>Key PointsAbbVie is a Dividend Aristocrat that also performed quite well over the past year.Gilead Sciences has increased its dividend 51% over the last five years and should keep the streak going in ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/16/3-pharma-stocks-with-especially-juicy-dividends/\">Source Link</a>\n\n</div>\n","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Pharma Stocks With Especially Juicy Dividends</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Pharma Stocks With Especially Juicy Dividends\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-17 15:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/16/3-pharma-stocks-with-especially-juicy-dividends/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Key PointsAbbVie is a Dividend Aristocrat that also performed quite well over the past year.Gilead Sciences has increased its dividend 51% over the last five years and should keep the streak going in ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/16/3-pharma-stocks-with-especially-juicy-dividends/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GILD","symbol_name":"吉利德科学","start_time":0,"source_url":"https://www.fool.com/investing/2022/01/16/3-pharma-stocks-with-especially-juicy-dividends/","article_id":"1103076176","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1103076176","pubTimestamp":1642404988,"sourceInfo":null,"weMediaInfo":null,"summary":"Key PointsAbbVie is a Dividend Aristocrat that also performed quite well over the past year.Gilead S","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"GILD":"吉利德科学","ABBV":"艾伯维公司","PFE":"辉瑞"},"translate_title":"3股股息特别丰厚的医药股","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABBV":0.9,"GILD":0.9,"PFE":0.9},"content_text":"Key PointsAbbVie is a Dividend Aristocrat that also performed quite well over the past year.Gilead Sciences has increased its dividend 51% over the last five years and should keep the streak going in 2022.Pfizer is a cash cow with a strong and stable dividend.Big pharmaceutical companies usually make big bucks. And many of them return a portion of their profits to investors in the form of dividends.We asked three Motley Fool contributors to pick the pharma stocks that they think have especially juicy dividends. Here's why they chose AbbVie, Gilead Sciences, and Pfizer.Keith Speights(AbbVie):There's so much to like about AbbVie's dividend that it's hard to know where to begin. But I'll start with its attractive yield of 4.2%. What's even better, though, is that AbbVie is a Dividend Aristocrat-- an elite group of S&P 500members that have increased their dividends for at least 25 consecutive years.Unlike some dividend stocks, AbbVie has also delivered strong growth lately. Its shares soared 26% last year. With dividends included, the drugmaker's total return easily beat the S&P 500's performance.There are a couple of concerns for AbbVie, though. The U.S. Food and Drug Administration (FDA) recentlyplaced additional warnings on the company's JAK inhibitor Rinvoq. This could limit the sales of the drug to some extent. Also, AbbVie's top-selling drug Humira faces biosimilar rivals in the U.S. beginning in 2023. Sales are expected to decline significantly.However, AbbVie's dividend shouldn't be threatened at all. The company could also continue generating solid growth in the second half of this decade after the initial impact of Humira losing exclusivity. AbbVie has several other growth drivers, including autoimmune disease drug Skyrizi and blood cancer drug Venclexta.David Jagielski ( Gilead Sciences):Investing in a high-yielding dividend stock can be a great way to make the most of your money. But to ensure that inflation isn't chipping away at that cash flow over time, you'll also want to invest in a company that raises its dividend payments. With Gilead Sciences, investors are getting the best of both worlds -- a high yield of around 4% that has also been growing over the years.Five years ago, Gilead was paying its investors a quarterly dividend of $0.47. Today, those payments are up to $0.71, rising by 51% during that time and averaging a compound annual growth rate of 8.6%. And that already-juicy dividend can get even more mouth-watering as the company's payout ratio sits below 50%.In Gilead's latest quarterly update, sales rose 13% year over year to $7.4 billion. The company also reported net income of $2.6 billion, which equated to a per-share (diluted) profit of $2.05. And in the nine months leading up to that date, the earnings per share (EPS) topped $4.63. That's easily enough to cover the current dividend, which on an annual basis would total $2.84. And it leaves room for some generous increases as well.Now may be an optimal time to buy Gilead stock. The company typically reports its fourth-quarter earnings in early February. Gilead could announce another dividend hike then as well. Since 2015 when the company began making dividend payments, Gilead has consistently raised its payouts each subsequent year (and normally in February).With solid financials and the company likely to continue receiving a boost from its COVID-19 treatment, Veklury, it's probable that this dividend could get even juicier than it already is today.Prosper Junior Bakiny(Pfizer):When it comes to dividend stocks, high yields are great, but the ability to sustain dividend increases is even better. That's what pharma giant Pfizer provides. The company's current yield of 2.75% is well above the S&P 500's average of 1.27%. But just as important is Pfizer's very conservative cash payout ratio of 29.64%. For context, a payout ratio below the 60% range is generally considered good.This implies that Pfizer has considerable room to sustain dividend increases in large part thanks to the cash it has been generating over the past year. Pfizer's free cash flow soared by 126.1% to $29.2 billion in the trailing twelve-month period. We can attribute that primarily to Pfizer's COVID-19 vaccine, Comirnaty. This vaccine has become ablockbuster product-- and then some -- in its first year on the market.Pfizer said it would generate $36 billion from Comirnaty in the fiscal year 2021. Given recent developments surrounding the pandemic, 2022 should be another excellent year for the vaccine. Management thinks sales of Comirnaty could come in at $29 billion this year. Pfizer's coronavirus-related business alone, which includes Comirnaty and Paxlovid, a COVID-19 therapy that recently earned authorization, will generate more sales than dozens of large corporations will this year.But Pfizer has other tools at its disposal. The company's anticoagulant Eliquis, cancer medicine Xtandi, as well as its biosimilar business, are meaningfully contributing to its overall performance. Even immunosuppressant Xeljanz could return to growth this yeardespite the regulatory headwinds it encountered last year.Lastly, Pfizer's pipeline includes 29 ongoing phase 3 clinical trials. Expect new products and label expansions to strengthen an already solid lineup.And all of this at a reasonable price, too. Pfizer is trading at just 9.1 times forward earnings compared to an average price-to-earnings ratio of 13.3 for the pharma industry.In short, Pfizer provides a little bit of everything most investors look for: high growth, reasonable value, and stable income in the form of dividends. Too juicy to pass up, indeed.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9004973446,"gmtCreate":1642490727858,"gmtModify":1676533715202,"author":{"id":"3584161011431512","authorId":"3584161011431512","name":"superpopo","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3584161011431512","idStr":"3584161011431512"},"htmlText":"Apple juice?","listText":"Apple juice?","text":"Apple juice?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9004973446","repostId":1103076176,"repostType":4,"repost":{"id":"1103076176","pubTimestamp":1642404988,"share":"https://ttm.financial/m/news/1103076176?lang=&edition=fundamental","pubTime":"2022-01-17 15:36","market":"us","language":"en","title":"3 Pharma Stocks With Especially Juicy Dividends","url":"https://stock-news.laohu8.com/highlight/detail?id=1103076176","media":"Motley Fool","summary":"Key PointsAbbVie is a Dividend Aristocrat that also performed quite well over the past year.Gilead S","content":"<html><head></head><body><p>Key Points</p><ul><li>AbbVie is a Dividend Aristocrat that also performed quite well over the past year.</li><li>Gilead Sciences has increased its dividend 51% over the last five years and should keep the streak going in 2022.</li><li>Pfizer is a cash cow with a strong and stable dividend.</li></ul><p>Big pharmaceutical companies usually make big bucks. And many of them return a portion of their profits to investors in the form of dividends.</p><p>We asked three Motley Fool contributors to pick the pharma stocks that they think have especially juicy dividends. Here&#39;s why they chose <a href=\"https://laohu8.com/S/ABBV\"><b>AbbVie</b></a>, <a href=\"https://laohu8.com/S/GILD\"><b>Gilead Sciences</b></a>, and <a href=\"https://laohu8.com/S/PFE\"><b>Pfizer</b></a>.</p><p><b>Keith Speights(</b><a href=\"https://laohu8.com/S/ABBV\"><b>AbbVie</b></a><b>):</b>There&#39;s so much to like about AbbVie&#39;s dividend that it&#39;s hard to know where to begin. But I&#39;ll start with its attractive yield of 4.2%. What&#39;s even better, though, is that AbbVie is a Dividend Aristocrat-- an elite group of <b>S&amp;P 500</b>members that have increased their dividends for at least 25 consecutive years.</p><p>Unlike some dividend stocks, AbbVie has also delivered strong growth lately. Its shares soared 26% last year. With dividends included, the drugmaker&#39;s total return easily beat the S&amp;P 500&#39;s performance.</p><p>There are a couple of concerns for AbbVie, though. The U.S. Food and Drug Administration (FDA) recentlyplaced additional warnings on the company&#39;s JAK inhibitor Rinvoq. This could limit the sales of the drug to some extent. Also, AbbVie&#39;s top-selling drug Humira faces biosimilar rivals in the U.S. beginning in 2023. Sales are expected to decline significantly.</p><p>However, AbbVie&#39;s dividend shouldn&#39;t be threatened at all. The company could also continue generating solid growth in the second half of this decade after the initial impact of Humira losing exclusivity. AbbVie has several other growth drivers, including autoimmune disease drug Skyrizi and blood cancer drug Venclexta.</p><p><b>David Jagielski</b> <b>(</b> <a href=\"https://laohu8.com/S/GILD\"><b>Gilead Sciences</b></a><b>):</b>Investing in a high-yielding dividend stock can be a great way to make the most of your money. But to ensure that inflation isn&#39;t chipping away at that cash flow over time, you&#39;ll also want to invest in a company that raises its dividend payments. With Gilead Sciences, investors are getting the best of both worlds -- a high yield of around 4% that has also been growing over the years.</p><p>Five years ago, Gilead was paying its investors a quarterly dividend of $0.47. Today, those payments are up to $0.71, rising by 51% during that time and averaging a compound annual growth rate of 8.6%. And that already-juicy dividend can get even more mouth-watering as the company&#39;s payout ratio sits below 50%.</p><p>In Gilead&#39;s latest quarterly update, sales rose 13% year over year to $7.4 billion. The company also reported net income of $2.6 billion, which equated to a per-share (diluted) profit of $2.05. And in the nine months leading up to that date, the earnings per share (EPS) topped $4.63. That&#39;s easily enough to cover the current dividend, which on an annual basis would total $2.84. And it leaves room for some generous increases as well.</p><p>Now may be an optimal time to buy Gilead stock. The company typically reports its fourth-quarter earnings in early February. Gilead could announce another dividend hike then as well. Since 2015 when the company began making dividend payments, Gilead has consistently raised its payouts each subsequent year (and normally in February).</p><p>With solid financials and the company likely to continue receiving a boost from its COVID-19 treatment, Veklury, it&#39;s probable that this dividend could get even juicier than it already is today.</p><p><b>Prosper Junior Bakiny(</b><a href=\"https://laohu8.com/S/PFE\"><b>Pfizer</b></a><b>):</b>When it comes to dividend stocks, high yields are great, but the ability to sustain dividend increases is even better. That&#39;s what pharma giant Pfizer provides. The company&#39;s current yield of 2.75% is well above the S&amp;P 500&#39;s average of 1.27%. But just as important is Pfizer&#39;s very conservative cash payout ratio of 29.64%. For context, a payout ratio below the 60% range is generally considered good.</p><p>This implies that Pfizer has considerable room to sustain dividend increases in large part thanks to the cash it has been generating over the past year. Pfizer&#39;s free cash flow soared by 126.1% to $29.2 billion in the trailing twelve-month period. We can attribute that primarily to Pfizer&#39;s COVID-19 vaccine, Comirnaty. This vaccine has become ablockbuster product-- and then some -- in its first year on the market.</p><p>Pfizer said it would generate $36 billion from Comirnaty in the fiscal year 2021. Given recent developments surrounding the pandemic, 2022 should be another excellent year for the vaccine. Management thinks sales of Comirnaty could come in at $29 billion this year. Pfizer&#39;s coronavirus-related business alone, which includes Comirnaty and Paxlovid, a COVID-19 therapy that recently earned authorization, will generate more sales than dozens of large corporations will this year.</p><p>But Pfizer has other tools at its disposal. The company&#39;s anticoagulant Eliquis, cancer medicine Xtandi, as well as its biosimilar business, are meaningfully contributing to its overall performance. Even immunosuppressant Xeljanz could return to growth this yeardespite the regulatory headwinds it encountered last year.</p><p>Lastly, Pfizer&#39;s pipeline includes 29 ongoing phase 3 clinical trials. Expect new products and label expansions to strengthen an already solid lineup.</p><p>And all of this at a reasonable price, too. Pfizer is trading at just 9.1 times forward earnings compared to an average price-to-earnings ratio of 13.3 for the pharma industry.</p><p>In short, Pfizer provides a little bit of everything most investors look for: high growth, reasonable value, and stable income in the form of dividends. Too juicy to pass up, indeed.</p><p></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Pharma Stocks With Especially Juicy Dividends</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Pharma Stocks With Especially Juicy Dividends\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-17 15:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/16/3-pharma-stocks-with-especially-juicy-dividends/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Key PointsAbbVie is a Dividend Aristocrat that also performed quite well over the past year.Gilead Sciences has increased its dividend 51% over the last five years and should keep the streak going in ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/16/3-pharma-stocks-with-especially-juicy-dividends/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GILD":"吉利德科学","ABBV":"艾伯维公司","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2022/01/16/3-pharma-stocks-with-especially-juicy-dividends/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1103076176","content_text":"Key PointsAbbVie is a Dividend Aristocrat that also performed quite well over the past year.Gilead Sciences has increased its dividend 51% over the last five years and should keep the streak going in 2022.Pfizer is a cash cow with a strong and stable dividend.Big pharmaceutical companies usually make big bucks. And many of them return a portion of their profits to investors in the form of dividends.We asked three Motley Fool contributors to pick the pharma stocks that they think have especially juicy dividends. Here's why they chose AbbVie, Gilead Sciences, and Pfizer.Keith Speights(AbbVie):There's so much to like about AbbVie's dividend that it's hard to know where to begin. But I'll start with its attractive yield of 4.2%. What's even better, though, is that AbbVie is a Dividend Aristocrat-- an elite group of S&P 500members that have increased their dividends for at least 25 consecutive years.Unlike some dividend stocks, AbbVie has also delivered strong growth lately. Its shares soared 26% last year. With dividends included, the drugmaker's total return easily beat the S&P 500's performance.There are a couple of concerns for AbbVie, though. The U.S. Food and Drug Administration (FDA) recentlyplaced additional warnings on the company's JAK inhibitor Rinvoq. This could limit the sales of the drug to some extent. Also, AbbVie's top-selling drug Humira faces biosimilar rivals in the U.S. beginning in 2023. Sales are expected to decline significantly.However, AbbVie's dividend shouldn't be threatened at all. The company could also continue generating solid growth in the second half of this decade after the initial impact of Humira losing exclusivity. AbbVie has several other growth drivers, including autoimmune disease drug Skyrizi and blood cancer drug Venclexta.David Jagielski ( Gilead Sciences):Investing in a high-yielding dividend stock can be a great way to make the most of your money. But to ensure that inflation isn't chipping away at that cash flow over time, you'll also want to invest in a company that raises its dividend payments. With Gilead Sciences, investors are getting the best of both worlds -- a high yield of around 4% that has also been growing over the years.Five years ago, Gilead was paying its investors a quarterly dividend of $0.47. Today, those payments are up to $0.71, rising by 51% during that time and averaging a compound annual growth rate of 8.6%. And that already-juicy dividend can get even more mouth-watering as the company's payout ratio sits below 50%.In Gilead's latest quarterly update, sales rose 13% year over year to $7.4 billion. The company also reported net income of $2.6 billion, which equated to a per-share (diluted) profit of $2.05. And in the nine months leading up to that date, the earnings per share (EPS) topped $4.63. That's easily enough to cover the current dividend, which on an annual basis would total $2.84. And it leaves room for some generous increases as well.Now may be an optimal time to buy Gilead stock. The company typically reports its fourth-quarter earnings in early February. Gilead could announce another dividend hike then as well. Since 2015 when the company began making dividend payments, Gilead has consistently raised its payouts each subsequent year (and normally in February).With solid financials and the company likely to continue receiving a boost from its COVID-19 treatment, Veklury, it's probable that this dividend could get even juicier than it already is today.Prosper Junior Bakiny(Pfizer):When it comes to dividend stocks, high yields are great, but the ability to sustain dividend increases is even better. That's what pharma giant Pfizer provides. The company's current yield of 2.75% is well above the S&P 500's average of 1.27%. But just as important is Pfizer's very conservative cash payout ratio of 29.64%. For context, a payout ratio below the 60% range is generally considered good.This implies that Pfizer has considerable room to sustain dividend increases in large part thanks to the cash it has been generating over the past year. Pfizer's free cash flow soared by 126.1% to $29.2 billion in the trailing twelve-month period. We can attribute that primarily to Pfizer's COVID-19 vaccine, Comirnaty. This vaccine has become ablockbuster product-- and then some -- in its first year on the market.Pfizer said it would generate $36 billion from Comirnaty in the fiscal year 2021. Given recent developments surrounding the pandemic, 2022 should be another excellent year for the vaccine. Management thinks sales of Comirnaty could come in at $29 billion this year. Pfizer's coronavirus-related business alone, which includes Comirnaty and Paxlovid, a COVID-19 therapy that recently earned authorization, will generate more sales than dozens of large corporations will this year.But Pfizer has other tools at its disposal. The company's anticoagulant Eliquis, cancer medicine Xtandi, as well as its biosimilar business, are meaningfully contributing to its overall performance. Even immunosuppressant Xeljanz could return to growth this yeardespite the regulatory headwinds it encountered last year.Lastly, Pfizer's pipeline includes 29 ongoing phase 3 clinical trials. Expect new products and label expansions to strengthen an already solid lineup.And all of this at a reasonable price, too. Pfizer is trading at just 9.1 times forward earnings compared to an average price-to-earnings ratio of 13.3 for the pharma industry.In short, Pfizer provides a little bit of everything most investors look for: high growth, reasonable value, and stable income in the form of dividends. Too juicy to pass up, indeed.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9004057176,"gmtCreate":1642463780650,"gmtModify":1676533712212,"author":{"id":"3583412008066274","authorId":"3583412008066274","name":"time to eat","avatar":"https://static.tigerbbs.com/c3d6a537cecde2d1daeefa1dd8ff6f99","vip":1,"crmLevel":6,"crmLevelSwitch":0,"authorIdStr":"3583412008066274","idStr":"3583412008066274"},"htmlText":"Just buy","listText":"Just buy","text":"Just buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9004057176","repostId":1103076176,"repostType":4,"repost":{"id":"1103076176","pubTimestamp":1642404988,"share":"https://ttm.financial/m/news/1103076176?lang=&edition=fundamental","pubTime":"2022-01-17 15:36","market":"us","language":"en","title":"3 Pharma Stocks With Especially Juicy Dividends","url":"https://stock-news.laohu8.com/highlight/detail?id=1103076176","media":"Motley Fool","summary":"Key PointsAbbVie is a Dividend Aristocrat that also performed quite well over the past year.Gilead S","content":"<html><head></head><body><p>Key Points</p><ul><li>AbbVie is a Dividend Aristocrat that also performed quite well over the past year.</li><li>Gilead Sciences has increased its dividend 51% over the last five years and should keep the streak going in 2022.</li><li>Pfizer is a cash cow with a strong and stable dividend.</li></ul><p>Big pharmaceutical companies usually make big bucks. And many of them return a portion of their profits to investors in the form of dividends.</p><p>We asked three Motley Fool contributors to pick the pharma stocks that they think have especially juicy dividends. Here&#39;s why they chose <a href=\"https://laohu8.com/S/ABBV\"><b>AbbVie</b></a>, <a href=\"https://laohu8.com/S/GILD\"><b>Gilead Sciences</b></a>, and <a href=\"https://laohu8.com/S/PFE\"><b>Pfizer</b></a>.</p><p><b>Keith Speights(</b><a href=\"https://laohu8.com/S/ABBV\"><b>AbbVie</b></a><b>):</b>There&#39;s so much to like about AbbVie&#39;s dividend that it&#39;s hard to know where to begin. But I&#39;ll start with its attractive yield of 4.2%. What&#39;s even better, though, is that AbbVie is a Dividend Aristocrat-- an elite group of <b>S&amp;P 500</b>members that have increased their dividends for at least 25 consecutive years.</p><p>Unlike some dividend stocks, AbbVie has also delivered strong growth lately. Its shares soared 26% last year. With dividends included, the drugmaker&#39;s total return easily beat the S&amp;P 500&#39;s performance.</p><p>There are a couple of concerns for AbbVie, though. The U.S. Food and Drug Administration (FDA) recentlyplaced additional warnings on the company&#39;s JAK inhibitor Rinvoq. This could limit the sales of the drug to some extent. Also, AbbVie&#39;s top-selling drug Humira faces biosimilar rivals in the U.S. beginning in 2023. Sales are expected to decline significantly.</p><p>However, AbbVie&#39;s dividend shouldn&#39;t be threatened at all. The company could also continue generating solid growth in the second half of this decade after the initial impact of Humira losing exclusivity. AbbVie has several other growth drivers, including autoimmune disease drug Skyrizi and blood cancer drug Venclexta.</p><p><b>David Jagielski</b> <b>(</b> <a href=\"https://laohu8.com/S/GILD\"><b>Gilead Sciences</b></a><b>):</b>Investing in a high-yielding dividend stock can be a great way to make the most of your money. But to ensure that inflation isn&#39;t chipping away at that cash flow over time, you&#39;ll also want to invest in a company that raises its dividend payments. With Gilead Sciences, investors are getting the best of both worlds -- a high yield of around 4% that has also been growing over the years.</p><p>Five years ago, Gilead was paying its investors a quarterly dividend of $0.47. Today, those payments are up to $0.71, rising by 51% during that time and averaging a compound annual growth rate of 8.6%. And that already-juicy dividend can get even more mouth-watering as the company&#39;s payout ratio sits below 50%.</p><p>In Gilead&#39;s latest quarterly update, sales rose 13% year over year to $7.4 billion. The company also reported net income of $2.6 billion, which equated to a per-share (diluted) profit of $2.05. And in the nine months leading up to that date, the earnings per share (EPS) topped $4.63. That&#39;s easily enough to cover the current dividend, which on an annual basis would total $2.84. And it leaves room for some generous increases as well.</p><p>Now may be an optimal time to buy Gilead stock. The company typically reports its fourth-quarter earnings in early February. Gilead could announce another dividend hike then as well. Since 2015 when the company began making dividend payments, Gilead has consistently raised its payouts each subsequent year (and normally in February).</p><p>With solid financials and the company likely to continue receiving a boost from its COVID-19 treatment, Veklury, it&#39;s probable that this dividend could get even juicier than it already is today.</p><p><b>Prosper Junior Bakiny(</b><a href=\"https://laohu8.com/S/PFE\"><b>Pfizer</b></a><b>):</b>When it comes to dividend stocks, high yields are great, but the ability to sustain dividend increases is even better. That&#39;s what pharma giant Pfizer provides. The company&#39;s current yield of 2.75% is well above the S&amp;P 500&#39;s average of 1.27%. But just as important is Pfizer&#39;s very conservative cash payout ratio of 29.64%. For context, a payout ratio below the 60% range is generally considered good.</p><p>This implies that Pfizer has considerable room to sustain dividend increases in large part thanks to the cash it has been generating over the past year. Pfizer&#39;s free cash flow soared by 126.1% to $29.2 billion in the trailing twelve-month period. We can attribute that primarily to Pfizer&#39;s COVID-19 vaccine, Comirnaty. This vaccine has become ablockbuster product-- and then some -- in its first year on the market.</p><p>Pfizer said it would generate $36 billion from Comirnaty in the fiscal year 2021. Given recent developments surrounding the pandemic, 2022 should be another excellent year for the vaccine. Management thinks sales of Comirnaty could come in at $29 billion this year. Pfizer&#39;s coronavirus-related business alone, which includes Comirnaty and Paxlovid, a COVID-19 therapy that recently earned authorization, will generate more sales than dozens of large corporations will this year.</p><p>But Pfizer has other tools at its disposal. The company&#39;s anticoagulant Eliquis, cancer medicine Xtandi, as well as its biosimilar business, are meaningfully contributing to its overall performance. Even immunosuppressant Xeljanz could return to growth this yeardespite the regulatory headwinds it encountered last year.</p><p>Lastly, Pfizer&#39;s pipeline includes 29 ongoing phase 3 clinical trials. Expect new products and label expansions to strengthen an already solid lineup.</p><p>And all of this at a reasonable price, too. Pfizer is trading at just 9.1 times forward earnings compared to an average price-to-earnings ratio of 13.3 for the pharma industry.</p><p>In short, Pfizer provides a little bit of everything most investors look for: high growth, reasonable value, and stable income in the form of dividends. Too juicy to pass up, indeed.</p><p></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Pharma Stocks With Especially Juicy Dividends</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Pharma Stocks With Especially Juicy Dividends\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-17 15:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/16/3-pharma-stocks-with-especially-juicy-dividends/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Key PointsAbbVie is a Dividend Aristocrat that also performed quite well over the past year.Gilead Sciences has increased its dividend 51% over the last five years and should keep the streak going in ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/16/3-pharma-stocks-with-especially-juicy-dividends/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GILD":"吉利德科学","ABBV":"艾伯维公司","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2022/01/16/3-pharma-stocks-with-especially-juicy-dividends/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1103076176","content_text":"Key PointsAbbVie is a Dividend Aristocrat that also performed quite well over the past year.Gilead Sciences has increased its dividend 51% over the last five years and should keep the streak going in 2022.Pfizer is a cash cow with a strong and stable dividend.Big pharmaceutical companies usually make big bucks. And many of them return a portion of their profits to investors in the form of dividends.We asked three Motley Fool contributors to pick the pharma stocks that they think have especially juicy dividends. Here's why they chose AbbVie, Gilead Sciences, and Pfizer.Keith Speights(AbbVie):There's so much to like about AbbVie's dividend that it's hard to know where to begin. But I'll start with its attractive yield of 4.2%. What's even better, though, is that AbbVie is a Dividend Aristocrat-- an elite group of S&P 500members that have increased their dividends for at least 25 consecutive years.Unlike some dividend stocks, AbbVie has also delivered strong growth lately. Its shares soared 26% last year. With dividends included, the drugmaker's total return easily beat the S&P 500's performance.There are a couple of concerns for AbbVie, though. The U.S. Food and Drug Administration (FDA) recentlyplaced additional warnings on the company's JAK inhibitor Rinvoq. This could limit the sales of the drug to some extent. Also, AbbVie's top-selling drug Humira faces biosimilar rivals in the U.S. beginning in 2023. Sales are expected to decline significantly.However, AbbVie's dividend shouldn't be threatened at all. The company could also continue generating solid growth in the second half of this decade after the initial impact of Humira losing exclusivity. AbbVie has several other growth drivers, including autoimmune disease drug Skyrizi and blood cancer drug Venclexta.David Jagielski ( Gilead Sciences):Investing in a high-yielding dividend stock can be a great way to make the most of your money. But to ensure that inflation isn't chipping away at that cash flow over time, you'll also want to invest in a company that raises its dividend payments. With Gilead Sciences, investors are getting the best of both worlds -- a high yield of around 4% that has also been growing over the years.Five years ago, Gilead was paying its investors a quarterly dividend of $0.47. Today, those payments are up to $0.71, rising by 51% during that time and averaging a compound annual growth rate of 8.6%. And that already-juicy dividend can get even more mouth-watering as the company's payout ratio sits below 50%.In Gilead's latest quarterly update, sales rose 13% year over year to $7.4 billion. The company also reported net income of $2.6 billion, which equated to a per-share (diluted) profit of $2.05. And in the nine months leading up to that date, the earnings per share (EPS) topped $4.63. That's easily enough to cover the current dividend, which on an annual basis would total $2.84. And it leaves room for some generous increases as well.Now may be an optimal time to buy Gilead stock. The company typically reports its fourth-quarter earnings in early February. Gilead could announce another dividend hike then as well. Since 2015 when the company began making dividend payments, Gilead has consistently raised its payouts each subsequent year (and normally in February).With solid financials and the company likely to continue receiving a boost from its COVID-19 treatment, Veklury, it's probable that this dividend could get even juicier than it already is today.Prosper Junior Bakiny(Pfizer):When it comes to dividend stocks, high yields are great, but the ability to sustain dividend increases is even better. That's what pharma giant Pfizer provides. The company's current yield of 2.75% is well above the S&P 500's average of 1.27%. But just as important is Pfizer's very conservative cash payout ratio of 29.64%. For context, a payout ratio below the 60% range is generally considered good.This implies that Pfizer has considerable room to sustain dividend increases in large part thanks to the cash it has been generating over the past year. Pfizer's free cash flow soared by 126.1% to $29.2 billion in the trailing twelve-month period. We can attribute that primarily to Pfizer's COVID-19 vaccine, Comirnaty. This vaccine has become ablockbuster product-- and then some -- in its first year on the market.Pfizer said it would generate $36 billion from Comirnaty in the fiscal year 2021. Given recent developments surrounding the pandemic, 2022 should be another excellent year for the vaccine. Management thinks sales of Comirnaty could come in at $29 billion this year. Pfizer's coronavirus-related business alone, which includes Comirnaty and Paxlovid, a COVID-19 therapy that recently earned authorization, will generate more sales than dozens of large corporations will this year.But Pfizer has other tools at its disposal. The company's anticoagulant Eliquis, cancer medicine Xtandi, as well as its biosimilar business, are meaningfully contributing to its overall performance. Even immunosuppressant Xeljanz could return to growth this yeardespite the regulatory headwinds it encountered last year.Lastly, Pfizer's pipeline includes 29 ongoing phase 3 clinical trials. Expect new products and label expansions to strengthen an already solid lineup.And all of this at a reasonable price, too. Pfizer is trading at just 9.1 times forward earnings compared to an average price-to-earnings ratio of 13.3 for the pharma industry.In short, Pfizer provides a little bit of everything most investors look for: high growth, reasonable value, and stable income in the form of dividends. Too juicy to pass up, indeed.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9004088758,"gmtCreate":1642459314942,"gmtModify":1676533711346,"author":{"id":"4094787128284850","authorId":"4094787128284850","name":"Gladys8jk","avatar":"https://static.tigerbbs.com/789bbf473867763cd44be080e269826d","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"4094787128284850","idStr":"4094787128284850"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9004088758","repostId":1103076176,"repostType":4,"repost":{"id":"1103076176","pubTimestamp":1642404988,"share":"https://ttm.financial/m/news/1103076176?lang=&edition=fundamental","pubTime":"2022-01-17 15:36","market":"us","language":"en","title":"3 Pharma Stocks With Especially Juicy Dividends","url":"https://stock-news.laohu8.com/highlight/detail?id=1103076176","media":"Motley Fool","summary":"Key PointsAbbVie is a Dividend Aristocrat that also performed quite well over the past year.Gilead S","content":"<html><head></head><body><p>Key Points</p><ul><li>AbbVie is a Dividend Aristocrat that also performed quite well over the past year.</li><li>Gilead Sciences has increased its dividend 51% over the last five years and should keep the streak going in 2022.</li><li>Pfizer is a cash cow with a strong and stable dividend.</li></ul><p>Big pharmaceutical companies usually make big bucks. And many of them return a portion of their profits to investors in the form of dividends.</p><p>We asked three Motley Fool contributors to pick the pharma stocks that they think have especially juicy dividends. Here&#39;s why they chose <a href=\"https://laohu8.com/S/ABBV\"><b>AbbVie</b></a>, <a href=\"https://laohu8.com/S/GILD\"><b>Gilead Sciences</b></a>, and <a href=\"https://laohu8.com/S/PFE\"><b>Pfizer</b></a>.</p><p><b>Keith Speights(</b><a href=\"https://laohu8.com/S/ABBV\"><b>AbbVie</b></a><b>):</b>There&#39;s so much to like about AbbVie&#39;s dividend that it&#39;s hard to know where to begin. But I&#39;ll start with its attractive yield of 4.2%. What&#39;s even better, though, is that AbbVie is a Dividend Aristocrat-- an elite group of <b>S&amp;P 500</b>members that have increased their dividends for at least 25 consecutive years.</p><p>Unlike some dividend stocks, AbbVie has also delivered strong growth lately. Its shares soared 26% last year. With dividends included, the drugmaker&#39;s total return easily beat the S&amp;P 500&#39;s performance.</p><p>There are a couple of concerns for AbbVie, though. The U.S. Food and Drug Administration (FDA) recentlyplaced additional warnings on the company&#39;s JAK inhibitor Rinvoq. This could limit the sales of the drug to some extent. Also, AbbVie&#39;s top-selling drug Humira faces biosimilar rivals in the U.S. beginning in 2023. Sales are expected to decline significantly.</p><p>However, AbbVie&#39;s dividend shouldn&#39;t be threatened at all. The company could also continue generating solid growth in the second half of this decade after the initial impact of Humira losing exclusivity. AbbVie has several other growth drivers, including autoimmune disease drug Skyrizi and blood cancer drug Venclexta.</p><p><b>David Jagielski</b> <b>(</b> <a href=\"https://laohu8.com/S/GILD\"><b>Gilead Sciences</b></a><b>):</b>Investing in a high-yielding dividend stock can be a great way to make the most of your money. But to ensure that inflation isn&#39;t chipping away at that cash flow over time, you&#39;ll also want to invest in a company that raises its dividend payments. With Gilead Sciences, investors are getting the best of both worlds -- a high yield of around 4% that has also been growing over the years.</p><p>Five years ago, Gilead was paying its investors a quarterly dividend of $0.47. Today, those payments are up to $0.71, rising by 51% during that time and averaging a compound annual growth rate of 8.6%. And that already-juicy dividend can get even more mouth-watering as the company&#39;s payout ratio sits below 50%.</p><p>In Gilead&#39;s latest quarterly update, sales rose 13% year over year to $7.4 billion. The company also reported net income of $2.6 billion, which equated to a per-share (diluted) profit of $2.05. And in the nine months leading up to that date, the earnings per share (EPS) topped $4.63. That&#39;s easily enough to cover the current dividend, which on an annual basis would total $2.84. And it leaves room for some generous increases as well.</p><p>Now may be an optimal time to buy Gilead stock. The company typically reports its fourth-quarter earnings in early February. Gilead could announce another dividend hike then as well. Since 2015 when the company began making dividend payments, Gilead has consistently raised its payouts each subsequent year (and normally in February).</p><p>With solid financials and the company likely to continue receiving a boost from its COVID-19 treatment, Veklury, it&#39;s probable that this dividend could get even juicier than it already is today.</p><p><b>Prosper Junior Bakiny(</b><a href=\"https://laohu8.com/S/PFE\"><b>Pfizer</b></a><b>):</b>When it comes to dividend stocks, high yields are great, but the ability to sustain dividend increases is even better. That&#39;s what pharma giant Pfizer provides. The company&#39;s current yield of 2.75% is well above the S&amp;P 500&#39;s average of 1.27%. But just as important is Pfizer&#39;s very conservative cash payout ratio of 29.64%. For context, a payout ratio below the 60% range is generally considered good.</p><p>This implies that Pfizer has considerable room to sustain dividend increases in large part thanks to the cash it has been generating over the past year. Pfizer&#39;s free cash flow soared by 126.1% to $29.2 billion in the trailing twelve-month period. We can attribute that primarily to Pfizer&#39;s COVID-19 vaccine, Comirnaty. This vaccine has become ablockbuster product-- and then some -- in its first year on the market.</p><p>Pfizer said it would generate $36 billion from Comirnaty in the fiscal year 2021. Given recent developments surrounding the pandemic, 2022 should be another excellent year for the vaccine. Management thinks sales of Comirnaty could come in at $29 billion this year. Pfizer&#39;s coronavirus-related business alone, which includes Comirnaty and Paxlovid, a COVID-19 therapy that recently earned authorization, will generate more sales than dozens of large corporations will this year.</p><p>But Pfizer has other tools at its disposal. The company&#39;s anticoagulant Eliquis, cancer medicine Xtandi, as well as its biosimilar business, are meaningfully contributing to its overall performance. Even immunosuppressant Xeljanz could return to growth this yeardespite the regulatory headwinds it encountered last year.</p><p>Lastly, Pfizer&#39;s pipeline includes 29 ongoing phase 3 clinical trials. Expect new products and label expansions to strengthen an already solid lineup.</p><p>And all of this at a reasonable price, too. Pfizer is trading at just 9.1 times forward earnings compared to an average price-to-earnings ratio of 13.3 for the pharma industry.</p><p>In short, Pfizer provides a little bit of everything most investors look for: high growth, reasonable value, and stable income in the form of dividends. Too juicy to pass up, indeed.</p><p></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Pharma Stocks With Especially Juicy Dividends</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Pharma Stocks With Especially Juicy Dividends\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-17 15:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/16/3-pharma-stocks-with-especially-juicy-dividends/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Key PointsAbbVie is a Dividend Aristocrat that also performed quite well over the past year.Gilead Sciences has increased its dividend 51% over the last five years and should keep the streak going in ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/16/3-pharma-stocks-with-especially-juicy-dividends/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GILD":"吉利德科学","ABBV":"艾伯维公司","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2022/01/16/3-pharma-stocks-with-especially-juicy-dividends/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1103076176","content_text":"Key PointsAbbVie is a Dividend Aristocrat that also performed quite well over the past year.Gilead Sciences has increased its dividend 51% over the last five years and should keep the streak going in 2022.Pfizer is a cash cow with a strong and stable dividend.Big pharmaceutical companies usually make big bucks. And many of them return a portion of their profits to investors in the form of dividends.We asked three Motley Fool contributors to pick the pharma stocks that they think have especially juicy dividends. Here's why they chose AbbVie, Gilead Sciences, and Pfizer.Keith Speights(AbbVie):There's so much to like about AbbVie's dividend that it's hard to know where to begin. But I'll start with its attractive yield of 4.2%. What's even better, though, is that AbbVie is a Dividend Aristocrat-- an elite group of S&P 500members that have increased their dividends for at least 25 consecutive years.Unlike some dividend stocks, AbbVie has also delivered strong growth lately. Its shares soared 26% last year. With dividends included, the drugmaker's total return easily beat the S&P 500's performance.There are a couple of concerns for AbbVie, though. The U.S. Food and Drug Administration (FDA) recentlyplaced additional warnings on the company's JAK inhibitor Rinvoq. This could limit the sales of the drug to some extent. Also, AbbVie's top-selling drug Humira faces biosimilar rivals in the U.S. beginning in 2023. Sales are expected to decline significantly.However, AbbVie's dividend shouldn't be threatened at all. The company could also continue generating solid growth in the second half of this decade after the initial impact of Humira losing exclusivity. AbbVie has several other growth drivers, including autoimmune disease drug Skyrizi and blood cancer drug Venclexta.David Jagielski ( Gilead Sciences):Investing in a high-yielding dividend stock can be a great way to make the most of your money. But to ensure that inflation isn't chipping away at that cash flow over time, you'll also want to invest in a company that raises its dividend payments. With Gilead Sciences, investors are getting the best of both worlds -- a high yield of around 4% that has also been growing over the years.Five years ago, Gilead was paying its investors a quarterly dividend of $0.47. Today, those payments are up to $0.71, rising by 51% during that time and averaging a compound annual growth rate of 8.6%. And that already-juicy dividend can get even more mouth-watering as the company's payout ratio sits below 50%.In Gilead's latest quarterly update, sales rose 13% year over year to $7.4 billion. The company also reported net income of $2.6 billion, which equated to a per-share (diluted) profit of $2.05. And in the nine months leading up to that date, the earnings per share (EPS) topped $4.63. That's easily enough to cover the current dividend, which on an annual basis would total $2.84. And it leaves room for some generous increases as well.Now may be an optimal time to buy Gilead stock. The company typically reports its fourth-quarter earnings in early February. Gilead could announce another dividend hike then as well. Since 2015 when the company began making dividend payments, Gilead has consistently raised its payouts each subsequent year (and normally in February).With solid financials and the company likely to continue receiving a boost from its COVID-19 treatment, Veklury, it's probable that this dividend could get even juicier than it already is today.Prosper Junior Bakiny(Pfizer):When it comes to dividend stocks, high yields are great, but the ability to sustain dividend increases is even better. That's what pharma giant Pfizer provides. The company's current yield of 2.75% is well above the S&P 500's average of 1.27%. But just as important is Pfizer's very conservative cash payout ratio of 29.64%. For context, a payout ratio below the 60% range is generally considered good.This implies that Pfizer has considerable room to sustain dividend increases in large part thanks to the cash it has been generating over the past year. Pfizer's free cash flow soared by 126.1% to $29.2 billion in the trailing twelve-month period. We can attribute that primarily to Pfizer's COVID-19 vaccine, Comirnaty. This vaccine has become ablockbuster product-- and then some -- in its first year on the market.Pfizer said it would generate $36 billion from Comirnaty in the fiscal year 2021. Given recent developments surrounding the pandemic, 2022 should be another excellent year for the vaccine. Management thinks sales of Comirnaty could come in at $29 billion this year. Pfizer's coronavirus-related business alone, which includes Comirnaty and Paxlovid, a COVID-19 therapy that recently earned authorization, will generate more sales than dozens of large corporations will this year.But Pfizer has other tools at its disposal. The company's anticoagulant Eliquis, cancer medicine Xtandi, as well as its biosimilar business, are meaningfully contributing to its overall performance. Even immunosuppressant Xeljanz could return to growth this yeardespite the regulatory headwinds it encountered last year.Lastly, Pfizer's pipeline includes 29 ongoing phase 3 clinical trials. Expect new products and label expansions to strengthen an already solid lineup.And all of this at a reasonable price, too. Pfizer is trading at just 9.1 times forward earnings compared to an average price-to-earnings ratio of 13.3 for the pharma industry.In short, Pfizer provides a little bit of everything most investors look for: high growth, reasonable value, and stable income in the form of dividends. Too juicy to pass up, indeed.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9004035773,"gmtCreate":1642455079317,"gmtModify":1676533710868,"author":{"id":"4092554906611330","authorId":"4092554906611330","name":"Samuel123win","avatar":"https://static.tigerbbs.com/fb615bd9d23d3ee707625d59ccb06f5e","vip":1,"hat":"https://static.tigerbbs.com/4c5ceab71416b120bab4604c0754b52a","crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"4092554906611330","idStr":"4092554906611330"},"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9004035773","repostId":1103076176,"repostType":4,"repost":{"id":"1103076176","pubTimestamp":1642404988,"share":"https://ttm.financial/m/news/1103076176?lang=&edition=fundamental","pubTime":"2022-01-17 15:36","market":"us","language":"en","title":"3 Pharma Stocks With Especially Juicy Dividends","url":"https://stock-news.laohu8.com/highlight/detail?id=1103076176","media":"Motley Fool","summary":"Key PointsAbbVie is a Dividend Aristocrat that also performed quite well over the past year.Gilead S","content":"<html><head></head><body><p>Key Points</p><ul><li>AbbVie is a Dividend Aristocrat that also performed quite well over the past year.</li><li>Gilead Sciences has increased its dividend 51% over the last five years and should keep the streak going in 2022.</li><li>Pfizer is a cash cow with a strong and stable dividend.</li></ul><p>Big pharmaceutical companies usually make big bucks. And many of them return a portion of their profits to investors in the form of dividends.</p><p>We asked three Motley Fool contributors to pick the pharma stocks that they think have especially juicy dividends. Here&#39;s why they chose <a href=\"https://laohu8.com/S/ABBV\"><b>AbbVie</b></a>, <a href=\"https://laohu8.com/S/GILD\"><b>Gilead Sciences</b></a>, and <a href=\"https://laohu8.com/S/PFE\"><b>Pfizer</b></a>.</p><p><b>Keith Speights(</b><a href=\"https://laohu8.com/S/ABBV\"><b>AbbVie</b></a><b>):</b>There&#39;s so much to like about AbbVie&#39;s dividend that it&#39;s hard to know where to begin. But I&#39;ll start with its attractive yield of 4.2%. What&#39;s even better, though, is that AbbVie is a Dividend Aristocrat-- an elite group of <b>S&amp;P 500</b>members that have increased their dividends for at least 25 consecutive years.</p><p>Unlike some dividend stocks, AbbVie has also delivered strong growth lately. Its shares soared 26% last year. With dividends included, the drugmaker&#39;s total return easily beat the S&amp;P 500&#39;s performance.</p><p>There are a couple of concerns for AbbVie, though. The U.S. Food and Drug Administration (FDA) recentlyplaced additional warnings on the company&#39;s JAK inhibitor Rinvoq. This could limit the sales of the drug to some extent. Also, AbbVie&#39;s top-selling drug Humira faces biosimilar rivals in the U.S. beginning in 2023. Sales are expected to decline significantly.</p><p>However, AbbVie&#39;s dividend shouldn&#39;t be threatened at all. The company could also continue generating solid growth in the second half of this decade after the initial impact of Humira losing exclusivity. AbbVie has several other growth drivers, including autoimmune disease drug Skyrizi and blood cancer drug Venclexta.</p><p><b>David Jagielski</b> <b>(</b> <a href=\"https://laohu8.com/S/GILD\"><b>Gilead Sciences</b></a><b>):</b>Investing in a high-yielding dividend stock can be a great way to make the most of your money. But to ensure that inflation isn&#39;t chipping away at that cash flow over time, you&#39;ll also want to invest in a company that raises its dividend payments. With Gilead Sciences, investors are getting the best of both worlds -- a high yield of around 4% that has also been growing over the years.</p><p>Five years ago, Gilead was paying its investors a quarterly dividend of $0.47. Today, those payments are up to $0.71, rising by 51% during that time and averaging a compound annual growth rate of 8.6%. And that already-juicy dividend can get even more mouth-watering as the company&#39;s payout ratio sits below 50%.</p><p>In Gilead&#39;s latest quarterly update, sales rose 13% year over year to $7.4 billion. The company also reported net income of $2.6 billion, which equated to a per-share (diluted) profit of $2.05. And in the nine months leading up to that date, the earnings per share (EPS) topped $4.63. That&#39;s easily enough to cover the current dividend, which on an annual basis would total $2.84. And it leaves room for some generous increases as well.</p><p>Now may be an optimal time to buy Gilead stock. The company typically reports its fourth-quarter earnings in early February. Gilead could announce another dividend hike then as well. Since 2015 when the company began making dividend payments, Gilead has consistently raised its payouts each subsequent year (and normally in February).</p><p>With solid financials and the company likely to continue receiving a boost from its COVID-19 treatment, Veklury, it&#39;s probable that this dividend could get even juicier than it already is today.</p><p><b>Prosper Junior Bakiny(</b><a href=\"https://laohu8.com/S/PFE\"><b>Pfizer</b></a><b>):</b>When it comes to dividend stocks, high yields are great, but the ability to sustain dividend increases is even better. That&#39;s what pharma giant Pfizer provides. The company&#39;s current yield of 2.75% is well above the S&amp;P 500&#39;s average of 1.27%. But just as important is Pfizer&#39;s very conservative cash payout ratio of 29.64%. For context, a payout ratio below the 60% range is generally considered good.</p><p>This implies that Pfizer has considerable room to sustain dividend increases in large part thanks to the cash it has been generating over the past year. Pfizer&#39;s free cash flow soared by 126.1% to $29.2 billion in the trailing twelve-month period. We can attribute that primarily to Pfizer&#39;s COVID-19 vaccine, Comirnaty. This vaccine has become ablockbuster product-- and then some -- in its first year on the market.</p><p>Pfizer said it would generate $36 billion from Comirnaty in the fiscal year 2021. Given recent developments surrounding the pandemic, 2022 should be another excellent year for the vaccine. Management thinks sales of Comirnaty could come in at $29 billion this year. Pfizer&#39;s coronavirus-related business alone, which includes Comirnaty and Paxlovid, a COVID-19 therapy that recently earned authorization, will generate more sales than dozens of large corporations will this year.</p><p>But Pfizer has other tools at its disposal. The company&#39;s anticoagulant Eliquis, cancer medicine Xtandi, as well as its biosimilar business, are meaningfully contributing to its overall performance. Even immunosuppressant Xeljanz could return to growth this yeardespite the regulatory headwinds it encountered last year.</p><p>Lastly, Pfizer&#39;s pipeline includes 29 ongoing phase 3 clinical trials. Expect new products and label expansions to strengthen an already solid lineup.</p><p>And all of this at a reasonable price, too. Pfizer is trading at just 9.1 times forward earnings compared to an average price-to-earnings ratio of 13.3 for the pharma industry.</p><p>In short, Pfizer provides a little bit of everything most investors look for: high growth, reasonable value, and stable income in the form of dividends. Too juicy to pass up, indeed.</p><p></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Pharma Stocks With Especially Juicy Dividends</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Pharma Stocks With Especially Juicy Dividends\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-17 15:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/16/3-pharma-stocks-with-especially-juicy-dividends/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Key PointsAbbVie is a Dividend Aristocrat that also performed quite well over the past year.Gilead Sciences has increased its dividend 51% over the last five years and should keep the streak going in ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/16/3-pharma-stocks-with-especially-juicy-dividends/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GILD":"吉利德科学","ABBV":"艾伯维公司","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2022/01/16/3-pharma-stocks-with-especially-juicy-dividends/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1103076176","content_text":"Key PointsAbbVie is a Dividend Aristocrat that also performed quite well over the past year.Gilead Sciences has increased its dividend 51% over the last five years and should keep the streak going in 2022.Pfizer is a cash cow with a strong and stable dividend.Big pharmaceutical companies usually make big bucks. And many of them return a portion of their profits to investors in the form of dividends.We asked three Motley Fool contributors to pick the pharma stocks that they think have especially juicy dividends. Here's why they chose AbbVie, Gilead Sciences, and Pfizer.Keith Speights(AbbVie):There's so much to like about AbbVie's dividend that it's hard to know where to begin. But I'll start with its attractive yield of 4.2%. What's even better, though, is that AbbVie is a Dividend Aristocrat-- an elite group of S&P 500members that have increased their dividends for at least 25 consecutive years.Unlike some dividend stocks, AbbVie has also delivered strong growth lately. Its shares soared 26% last year. With dividends included, the drugmaker's total return easily beat the S&P 500's performance.There are a couple of concerns for AbbVie, though. The U.S. Food and Drug Administration (FDA) recentlyplaced additional warnings on the company's JAK inhibitor Rinvoq. This could limit the sales of the drug to some extent. Also, AbbVie's top-selling drug Humira faces biosimilar rivals in the U.S. beginning in 2023. Sales are expected to decline significantly.However, AbbVie's dividend shouldn't be threatened at all. The company could also continue generating solid growth in the second half of this decade after the initial impact of Humira losing exclusivity. AbbVie has several other growth drivers, including autoimmune disease drug Skyrizi and blood cancer drug Venclexta.David Jagielski ( Gilead Sciences):Investing in a high-yielding dividend stock can be a great way to make the most of your money. But to ensure that inflation isn't chipping away at that cash flow over time, you'll also want to invest in a company that raises its dividend payments. With Gilead Sciences, investors are getting the best of both worlds -- a high yield of around 4% that has also been growing over the years.Five years ago, Gilead was paying its investors a quarterly dividend of $0.47. Today, those payments are up to $0.71, rising by 51% during that time and averaging a compound annual growth rate of 8.6%. And that already-juicy dividend can get even more mouth-watering as the company's payout ratio sits below 50%.In Gilead's latest quarterly update, sales rose 13% year over year to $7.4 billion. The company also reported net income of $2.6 billion, which equated to a per-share (diluted) profit of $2.05. And in the nine months leading up to that date, the earnings per share (EPS) topped $4.63. That's easily enough to cover the current dividend, which on an annual basis would total $2.84. And it leaves room for some generous increases as well.Now may be an optimal time to buy Gilead stock. The company typically reports its fourth-quarter earnings in early February. Gilead could announce another dividend hike then as well. Since 2015 when the company began making dividend payments, Gilead has consistently raised its payouts each subsequent year (and normally in February).With solid financials and the company likely to continue receiving a boost from its COVID-19 treatment, Veklury, it's probable that this dividend could get even juicier than it already is today.Prosper Junior Bakiny(Pfizer):When it comes to dividend stocks, high yields are great, but the ability to sustain dividend increases is even better. That's what pharma giant Pfizer provides. The company's current yield of 2.75% is well above the S&P 500's average of 1.27%. But just as important is Pfizer's very conservative cash payout ratio of 29.64%. For context, a payout ratio below the 60% range is generally considered good.This implies that Pfizer has considerable room to sustain dividend increases in large part thanks to the cash it has been generating over the past year. Pfizer's free cash flow soared by 126.1% to $29.2 billion in the trailing twelve-month period. We can attribute that primarily to Pfizer's COVID-19 vaccine, Comirnaty. This vaccine has become ablockbuster product-- and then some -- in its first year on the market.Pfizer said it would generate $36 billion from Comirnaty in the fiscal year 2021. Given recent developments surrounding the pandemic, 2022 should be another excellent year for the vaccine. Management thinks sales of Comirnaty could come in at $29 billion this year. Pfizer's coronavirus-related business alone, which includes Comirnaty and Paxlovid, a COVID-19 therapy that recently earned authorization, will generate more sales than dozens of large corporations will this year.But Pfizer has other tools at its disposal. The company's anticoagulant Eliquis, cancer medicine Xtandi, as well as its biosimilar business, are meaningfully contributing to its overall performance. Even immunosuppressant Xeljanz could return to growth this yeardespite the regulatory headwinds it encountered last year.Lastly, Pfizer's pipeline includes 29 ongoing phase 3 clinical trials. Expect new products and label expansions to strengthen an already solid lineup.And all of this at a reasonable price, too. Pfizer is trading at just 9.1 times forward earnings compared to an average price-to-earnings ratio of 13.3 for the pharma industry.In short, Pfizer provides a little bit of everything most investors look for: high growth, reasonable value, and stable income in the form of dividends. Too juicy to pass up, indeed.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9004035454,"gmtCreate":1642455074971,"gmtModify":1676533710868,"author":{"id":"4100520219096230","authorId":"4100520219096230","name":"Piret","avatar":"https://static.tigerbbs.com/32af1c6079ca483ba4808b65db688b5e","vip":1,"crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"4100520219096230","idStr":"4100520219096230"},"htmlText":"Okay","listText":"Okay","text":"Okay","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9004035454","repostId":1103076176,"repostType":4,"repost":{"id":"1103076176","pubTimestamp":1642404988,"share":"https://ttm.financial/m/news/1103076176?lang=&edition=fundamental","pubTime":"2022-01-17 15:36","market":"us","language":"en","title":"3 Pharma Stocks With Especially Juicy Dividends","url":"https://stock-news.laohu8.com/highlight/detail?id=1103076176","media":"Motley Fool","summary":"Key PointsAbbVie is a Dividend Aristocrat that also performed quite well over the past year.Gilead S","content":"<html><head></head><body><p>Key Points</p><ul><li>AbbVie is a Dividend Aristocrat that also performed quite well over the past year.</li><li>Gilead Sciences has increased its dividend 51% over the last five years and should keep the streak going in 2022.</li><li>Pfizer is a cash cow with a strong and stable dividend.</li></ul><p>Big pharmaceutical companies usually make big bucks. And many of them return a portion of their profits to investors in the form of dividends.</p><p>We asked three Motley Fool contributors to pick the pharma stocks that they think have especially juicy dividends. Here&#39;s why they chose <a href=\"https://laohu8.com/S/ABBV\"><b>AbbVie</b></a>, <a href=\"https://laohu8.com/S/GILD\"><b>Gilead Sciences</b></a>, and <a href=\"https://laohu8.com/S/PFE\"><b>Pfizer</b></a>.</p><p><b>Keith Speights(</b><a href=\"https://laohu8.com/S/ABBV\"><b>AbbVie</b></a><b>):</b>There&#39;s so much to like about AbbVie&#39;s dividend that it&#39;s hard to know where to begin. But I&#39;ll start with its attractive yield of 4.2%. What&#39;s even better, though, is that AbbVie is a Dividend Aristocrat-- an elite group of <b>S&amp;P 500</b>members that have increased their dividends for at least 25 consecutive years.</p><p>Unlike some dividend stocks, AbbVie has also delivered strong growth lately. Its shares soared 26% last year. With dividends included, the drugmaker&#39;s total return easily beat the S&amp;P 500&#39;s performance.</p><p>There are a couple of concerns for AbbVie, though. The U.S. Food and Drug Administration (FDA) recentlyplaced additional warnings on the company&#39;s JAK inhibitor Rinvoq. This could limit the sales of the drug to some extent. Also, AbbVie&#39;s top-selling drug Humira faces biosimilar rivals in the U.S. beginning in 2023. Sales are expected to decline significantly.</p><p>However, AbbVie&#39;s dividend shouldn&#39;t be threatened at all. The company could also continue generating solid growth in the second half of this decade after the initial impact of Humira losing exclusivity. AbbVie has several other growth drivers, including autoimmune disease drug Skyrizi and blood cancer drug Venclexta.</p><p><b>David Jagielski</b> <b>(</b> <a href=\"https://laohu8.com/S/GILD\"><b>Gilead Sciences</b></a><b>):</b>Investing in a high-yielding dividend stock can be a great way to make the most of your money. But to ensure that inflation isn&#39;t chipping away at that cash flow over time, you&#39;ll also want to invest in a company that raises its dividend payments. With Gilead Sciences, investors are getting the best of both worlds -- a high yield of around 4% that has also been growing over the years.</p><p>Five years ago, Gilead was paying its investors a quarterly dividend of $0.47. Today, those payments are up to $0.71, rising by 51% during that time and averaging a compound annual growth rate of 8.6%. And that already-juicy dividend can get even more mouth-watering as the company&#39;s payout ratio sits below 50%.</p><p>In Gilead&#39;s latest quarterly update, sales rose 13% year over year to $7.4 billion. The company also reported net income of $2.6 billion, which equated to a per-share (diluted) profit of $2.05. And in the nine months leading up to that date, the earnings per share (EPS) topped $4.63. That&#39;s easily enough to cover the current dividend, which on an annual basis would total $2.84. And it leaves room for some generous increases as well.</p><p>Now may be an optimal time to buy Gilead stock. The company typically reports its fourth-quarter earnings in early February. Gilead could announce another dividend hike then as well. Since 2015 when the company began making dividend payments, Gilead has consistently raised its payouts each subsequent year (and normally in February).</p><p>With solid financials and the company likely to continue receiving a boost from its COVID-19 treatment, Veklury, it&#39;s probable that this dividend could get even juicier than it already is today.</p><p><b>Prosper Junior Bakiny(</b><a href=\"https://laohu8.com/S/PFE\"><b>Pfizer</b></a><b>):</b>When it comes to dividend stocks, high yields are great, but the ability to sustain dividend increases is even better. That&#39;s what pharma giant Pfizer provides. The company&#39;s current yield of 2.75% is well above the S&amp;P 500&#39;s average of 1.27%. But just as important is Pfizer&#39;s very conservative cash payout ratio of 29.64%. For context, a payout ratio below the 60% range is generally considered good.</p><p>This implies that Pfizer has considerable room to sustain dividend increases in large part thanks to the cash it has been generating over the past year. Pfizer&#39;s free cash flow soared by 126.1% to $29.2 billion in the trailing twelve-month period. We can attribute that primarily to Pfizer&#39;s COVID-19 vaccine, Comirnaty. This vaccine has become ablockbuster product-- and then some -- in its first year on the market.</p><p>Pfizer said it would generate $36 billion from Comirnaty in the fiscal year 2021. Given recent developments surrounding the pandemic, 2022 should be another excellent year for the vaccine. Management thinks sales of Comirnaty could come in at $29 billion this year. Pfizer&#39;s coronavirus-related business alone, which includes Comirnaty and Paxlovid, a COVID-19 therapy that recently earned authorization, will generate more sales than dozens of large corporations will this year.</p><p>But Pfizer has other tools at its disposal. The company&#39;s anticoagulant Eliquis, cancer medicine Xtandi, as well as its biosimilar business, are meaningfully contributing to its overall performance. Even immunosuppressant Xeljanz could return to growth this yeardespite the regulatory headwinds it encountered last year.</p><p>Lastly, Pfizer&#39;s pipeline includes 29 ongoing phase 3 clinical trials. Expect new products and label expansions to strengthen an already solid lineup.</p><p>And all of this at a reasonable price, too. Pfizer is trading at just 9.1 times forward earnings compared to an average price-to-earnings ratio of 13.3 for the pharma industry.</p><p>In short, Pfizer provides a little bit of everything most investors look for: high growth, reasonable value, and stable income in the form of dividends. Too juicy to pass up, indeed.</p><p></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Pharma Stocks With Especially Juicy Dividends</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Pharma Stocks With Especially Juicy Dividends\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-17 15:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/16/3-pharma-stocks-with-especially-juicy-dividends/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Key PointsAbbVie is a Dividend Aristocrat that also performed quite well over the past year.Gilead Sciences has increased its dividend 51% over the last five years and should keep the streak going in ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/16/3-pharma-stocks-with-especially-juicy-dividends/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GILD":"吉利德科学","ABBV":"艾伯维公司","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2022/01/16/3-pharma-stocks-with-especially-juicy-dividends/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1103076176","content_text":"Key PointsAbbVie is a Dividend Aristocrat that also performed quite well over the past year.Gilead Sciences has increased its dividend 51% over the last five years and should keep the streak going in 2022.Pfizer is a cash cow with a strong and stable dividend.Big pharmaceutical companies usually make big bucks. And many of them return a portion of their profits to investors in the form of dividends.We asked three Motley Fool contributors to pick the pharma stocks that they think have especially juicy dividends. Here's why they chose AbbVie, Gilead Sciences, and Pfizer.Keith Speights(AbbVie):There's so much to like about AbbVie's dividend that it's hard to know where to begin. But I'll start with its attractive yield of 4.2%. What's even better, though, is that AbbVie is a Dividend Aristocrat-- an elite group of S&P 500members that have increased their dividends for at least 25 consecutive years.Unlike some dividend stocks, AbbVie has also delivered strong growth lately. Its shares soared 26% last year. With dividends included, the drugmaker's total return easily beat the S&P 500's performance.There are a couple of concerns for AbbVie, though. The U.S. Food and Drug Administration (FDA) recentlyplaced additional warnings on the company's JAK inhibitor Rinvoq. This could limit the sales of the drug to some extent. Also, AbbVie's top-selling drug Humira faces biosimilar rivals in the U.S. beginning in 2023. Sales are expected to decline significantly.However, AbbVie's dividend shouldn't be threatened at all. The company could also continue generating solid growth in the second half of this decade after the initial impact of Humira losing exclusivity. AbbVie has several other growth drivers, including autoimmune disease drug Skyrizi and blood cancer drug Venclexta.David Jagielski ( Gilead Sciences):Investing in a high-yielding dividend stock can be a great way to make the most of your money. But to ensure that inflation isn't chipping away at that cash flow over time, you'll also want to invest in a company that raises its dividend payments. With Gilead Sciences, investors are getting the best of both worlds -- a high yield of around 4% that has also been growing over the years.Five years ago, Gilead was paying its investors a quarterly dividend of $0.47. Today, those payments are up to $0.71, rising by 51% during that time and averaging a compound annual growth rate of 8.6%. And that already-juicy dividend can get even more mouth-watering as the company's payout ratio sits below 50%.In Gilead's latest quarterly update, sales rose 13% year over year to $7.4 billion. The company also reported net income of $2.6 billion, which equated to a per-share (diluted) profit of $2.05. And in the nine months leading up to that date, the earnings per share (EPS) topped $4.63. That's easily enough to cover the current dividend, which on an annual basis would total $2.84. And it leaves room for some generous increases as well.Now may be an optimal time to buy Gilead stock. The company typically reports its fourth-quarter earnings in early February. Gilead could announce another dividend hike then as well. Since 2015 when the company began making dividend payments, Gilead has consistently raised its payouts each subsequent year (and normally in February).With solid financials and the company likely to continue receiving a boost from its COVID-19 treatment, Veklury, it's probable that this dividend could get even juicier than it already is today.Prosper Junior Bakiny(Pfizer):When it comes to dividend stocks, high yields are great, but the ability to sustain dividend increases is even better. That's what pharma giant Pfizer provides. The company's current yield of 2.75% is well above the S&P 500's average of 1.27%. But just as important is Pfizer's very conservative cash payout ratio of 29.64%. For context, a payout ratio below the 60% range is generally considered good.This implies that Pfizer has considerable room to sustain dividend increases in large part thanks to the cash it has been generating over the past year. Pfizer's free cash flow soared by 126.1% to $29.2 billion in the trailing twelve-month period. We can attribute that primarily to Pfizer's COVID-19 vaccine, Comirnaty. This vaccine has become ablockbuster product-- and then some -- in its first year on the market.Pfizer said it would generate $36 billion from Comirnaty in the fiscal year 2021. Given recent developments surrounding the pandemic, 2022 should be another excellent year for the vaccine. Management thinks sales of Comirnaty could come in at $29 billion this year. Pfizer's coronavirus-related business alone, which includes Comirnaty and Paxlovid, a COVID-19 therapy that recently earned authorization, will generate more sales than dozens of large corporations will this year.But Pfizer has other tools at its disposal. The company's anticoagulant Eliquis, cancer medicine Xtandi, as well as its biosimilar business, are meaningfully contributing to its overall performance. Even immunosuppressant Xeljanz could return to growth this yeardespite the regulatory headwinds it encountered last year.Lastly, Pfizer's pipeline includes 29 ongoing phase 3 clinical trials. Expect new products and label expansions to strengthen an already solid lineup.And all of this at a reasonable price, too. Pfizer is trading at just 9.1 times forward earnings compared to an average price-to-earnings ratio of 13.3 for the pharma industry.In short, Pfizer provides a little bit of everything most investors look for: high growth, reasonable value, and stable income in the form of dividends. Too juicy to pass up, indeed.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9004093087,"gmtCreate":1642434394570,"gmtModify":1676533710466,"author":{"id":"3570853427202414","authorId":"3570853427202414","name":"BKT","avatar":"https://community-static.tradeup.com/news/15cb8e8f0a7c44ca01c83b3bfdddbd86","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3570853427202414","idStr":"3570853427202414"},"htmlText":"Good. Pls like thanks.","listText":"Good. Pls like thanks.","text":"Good. Pls like thanks.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9004093087","repostId":1103076176,"repostType":4,"repost":{"id":"1103076176","pubTimestamp":1642404988,"share":"https://ttm.financial/m/news/1103076176?lang=&edition=fundamental","pubTime":"2022-01-17 15:36","market":"us","language":"en","title":"3 Pharma Stocks With Especially Juicy Dividends","url":"https://stock-news.laohu8.com/highlight/detail?id=1103076176","media":"Motley Fool","summary":"Key PointsAbbVie is a Dividend Aristocrat that also performed quite well over the past year.Gilead S","content":"<html><head></head><body><p>Key Points</p><ul><li>AbbVie is a Dividend Aristocrat that also performed quite well over the past year.</li><li>Gilead Sciences has increased its dividend 51% over the last five years and should keep the streak going in 2022.</li><li>Pfizer is a cash cow with a strong and stable dividend.</li></ul><p>Big pharmaceutical companies usually make big bucks. And many of them return a portion of their profits to investors in the form of dividends.</p><p>We asked three Motley Fool contributors to pick the pharma stocks that they think have especially juicy dividends. Here&#39;s why they chose <a href=\"https://laohu8.com/S/ABBV\"><b>AbbVie</b></a>, <a href=\"https://laohu8.com/S/GILD\"><b>Gilead Sciences</b></a>, and <a href=\"https://laohu8.com/S/PFE\"><b>Pfizer</b></a>.</p><p><b>Keith Speights(</b><a href=\"https://laohu8.com/S/ABBV\"><b>AbbVie</b></a><b>):</b>There&#39;s so much to like about AbbVie&#39;s dividend that it&#39;s hard to know where to begin. But I&#39;ll start with its attractive yield of 4.2%. What&#39;s even better, though, is that AbbVie is a Dividend Aristocrat-- an elite group of <b>S&amp;P 500</b>members that have increased their dividends for at least 25 consecutive years.</p><p>Unlike some dividend stocks, AbbVie has also delivered strong growth lately. Its shares soared 26% last year. With dividends included, the drugmaker&#39;s total return easily beat the S&amp;P 500&#39;s performance.</p><p>There are a couple of concerns for AbbVie, though. The U.S. Food and Drug Administration (FDA) recentlyplaced additional warnings on the company&#39;s JAK inhibitor Rinvoq. This could limit the sales of the drug to some extent. Also, AbbVie&#39;s top-selling drug Humira faces biosimilar rivals in the U.S. beginning in 2023. Sales are expected to decline significantly.</p><p>However, AbbVie&#39;s dividend shouldn&#39;t be threatened at all. The company could also continue generating solid growth in the second half of this decade after the initial impact of Humira losing exclusivity. AbbVie has several other growth drivers, including autoimmune disease drug Skyrizi and blood cancer drug Venclexta.</p><p><b>David Jagielski</b> <b>(</b> <a href=\"https://laohu8.com/S/GILD\"><b>Gilead Sciences</b></a><b>):</b>Investing in a high-yielding dividend stock can be a great way to make the most of your money. But to ensure that inflation isn&#39;t chipping away at that cash flow over time, you&#39;ll also want to invest in a company that raises its dividend payments. With Gilead Sciences, investors are getting the best of both worlds -- a high yield of around 4% that has also been growing over the years.</p><p>Five years ago, Gilead was paying its investors a quarterly dividend of $0.47. Today, those payments are up to $0.71, rising by 51% during that time and averaging a compound annual growth rate of 8.6%. And that already-juicy dividend can get even more mouth-watering as the company&#39;s payout ratio sits below 50%.</p><p>In Gilead&#39;s latest quarterly update, sales rose 13% year over year to $7.4 billion. The company also reported net income of $2.6 billion, which equated to a per-share (diluted) profit of $2.05. And in the nine months leading up to that date, the earnings per share (EPS) topped $4.63. That&#39;s easily enough to cover the current dividend, which on an annual basis would total $2.84. And it leaves room for some generous increases as well.</p><p>Now may be an optimal time to buy Gilead stock. The company typically reports its fourth-quarter earnings in early February. Gilead could announce another dividend hike then as well. Since 2015 when the company began making dividend payments, Gilead has consistently raised its payouts each subsequent year (and normally in February).</p><p>With solid financials and the company likely to continue receiving a boost from its COVID-19 treatment, Veklury, it&#39;s probable that this dividend could get even juicier than it already is today.</p><p><b>Prosper Junior Bakiny(</b><a href=\"https://laohu8.com/S/PFE\"><b>Pfizer</b></a><b>):</b>When it comes to dividend stocks, high yields are great, but the ability to sustain dividend increases is even better. That&#39;s what pharma giant Pfizer provides. The company&#39;s current yield of 2.75% is well above the S&amp;P 500&#39;s average of 1.27%. But just as important is Pfizer&#39;s very conservative cash payout ratio of 29.64%. For context, a payout ratio below the 60% range is generally considered good.</p><p>This implies that Pfizer has considerable room to sustain dividend increases in large part thanks to the cash it has been generating over the past year. Pfizer&#39;s free cash flow soared by 126.1% to $29.2 billion in the trailing twelve-month period. We can attribute that primarily to Pfizer&#39;s COVID-19 vaccine, Comirnaty. This vaccine has become ablockbuster product-- and then some -- in its first year on the market.</p><p>Pfizer said it would generate $36 billion from Comirnaty in the fiscal year 2021. Given recent developments surrounding the pandemic, 2022 should be another excellent year for the vaccine. Management thinks sales of Comirnaty could come in at $29 billion this year. Pfizer&#39;s coronavirus-related business alone, which includes Comirnaty and Paxlovid, a COVID-19 therapy that recently earned authorization, will generate more sales than dozens of large corporations will this year.</p><p>But Pfizer has other tools at its disposal. The company&#39;s anticoagulant Eliquis, cancer medicine Xtandi, as well as its biosimilar business, are meaningfully contributing to its overall performance. Even immunosuppressant Xeljanz could return to growth this yeardespite the regulatory headwinds it encountered last year.</p><p>Lastly, Pfizer&#39;s pipeline includes 29 ongoing phase 3 clinical trials. Expect new products and label expansions to strengthen an already solid lineup.</p><p>And all of this at a reasonable price, too. Pfizer is trading at just 9.1 times forward earnings compared to an average price-to-earnings ratio of 13.3 for the pharma industry.</p><p>In short, Pfizer provides a little bit of everything most investors look for: high growth, reasonable value, and stable income in the form of dividends. Too juicy to pass up, indeed.</p><p></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Pharma Stocks With Especially Juicy Dividends</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Pharma Stocks With Especially Juicy Dividends\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-17 15:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/16/3-pharma-stocks-with-especially-juicy-dividends/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Key PointsAbbVie is a Dividend Aristocrat that also performed quite well over the past year.Gilead Sciences has increased its dividend 51% over the last five years and should keep the streak going in ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/16/3-pharma-stocks-with-especially-juicy-dividends/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GILD":"吉利德科学","ABBV":"艾伯维公司","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2022/01/16/3-pharma-stocks-with-especially-juicy-dividends/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1103076176","content_text":"Key PointsAbbVie is a Dividend Aristocrat that also performed quite well over the past year.Gilead Sciences has increased its dividend 51% over the last five years and should keep the streak going in 2022.Pfizer is a cash cow with a strong and stable dividend.Big pharmaceutical companies usually make big bucks. And many of them return a portion of their profits to investors in the form of dividends.We asked three Motley Fool contributors to pick the pharma stocks that they think have especially juicy dividends. Here's why they chose AbbVie, Gilead Sciences, and Pfizer.Keith Speights(AbbVie):There's so much to like about AbbVie's dividend that it's hard to know where to begin. But I'll start with its attractive yield of 4.2%. What's even better, though, is that AbbVie is a Dividend Aristocrat-- an elite group of S&P 500members that have increased their dividends for at least 25 consecutive years.Unlike some dividend stocks, AbbVie has also delivered strong growth lately. Its shares soared 26% last year. With dividends included, the drugmaker's total return easily beat the S&P 500's performance.There are a couple of concerns for AbbVie, though. The U.S. Food and Drug Administration (FDA) recentlyplaced additional warnings on the company's JAK inhibitor Rinvoq. This could limit the sales of the drug to some extent. Also, AbbVie's top-selling drug Humira faces biosimilar rivals in the U.S. beginning in 2023. Sales are expected to decline significantly.However, AbbVie's dividend shouldn't be threatened at all. The company could also continue generating solid growth in the second half of this decade after the initial impact of Humira losing exclusivity. AbbVie has several other growth drivers, including autoimmune disease drug Skyrizi and blood cancer drug Venclexta.David Jagielski ( Gilead Sciences):Investing in a high-yielding dividend stock can be a great way to make the most of your money. But to ensure that inflation isn't chipping away at that cash flow over time, you'll also want to invest in a company that raises its dividend payments. With Gilead Sciences, investors are getting the best of both worlds -- a high yield of around 4% that has also been growing over the years.Five years ago, Gilead was paying its investors a quarterly dividend of $0.47. Today, those payments are up to $0.71, rising by 51% during that time and averaging a compound annual growth rate of 8.6%. And that already-juicy dividend can get even more mouth-watering as the company's payout ratio sits below 50%.In Gilead's latest quarterly update, sales rose 13% year over year to $7.4 billion. The company also reported net income of $2.6 billion, which equated to a per-share (diluted) profit of $2.05. And in the nine months leading up to that date, the earnings per share (EPS) topped $4.63. That's easily enough to cover the current dividend, which on an annual basis would total $2.84. And it leaves room for some generous increases as well.Now may be an optimal time to buy Gilead stock. The company typically reports its fourth-quarter earnings in early February. Gilead could announce another dividend hike then as well. Since 2015 when the company began making dividend payments, Gilead has consistently raised its payouts each subsequent year (and normally in February).With solid financials and the company likely to continue receiving a boost from its COVID-19 treatment, Veklury, it's probable that this dividend could get even juicier than it already is today.Prosper Junior Bakiny(Pfizer):When it comes to dividend stocks, high yields are great, but the ability to sustain dividend increases is even better. That's what pharma giant Pfizer provides. The company's current yield of 2.75% is well above the S&P 500's average of 1.27%. But just as important is Pfizer's very conservative cash payout ratio of 29.64%. For context, a payout ratio below the 60% range is generally considered good.This implies that Pfizer has considerable room to sustain dividend increases in large part thanks to the cash it has been generating over the past year. Pfizer's free cash flow soared by 126.1% to $29.2 billion in the trailing twelve-month period. We can attribute that primarily to Pfizer's COVID-19 vaccine, Comirnaty. This vaccine has become ablockbuster product-- and then some -- in its first year on the market.Pfizer said it would generate $36 billion from Comirnaty in the fiscal year 2021. Given recent developments surrounding the pandemic, 2022 should be another excellent year for the vaccine. Management thinks sales of Comirnaty could come in at $29 billion this year. Pfizer's coronavirus-related business alone, which includes Comirnaty and Paxlovid, a COVID-19 therapy that recently earned authorization, will generate more sales than dozens of large corporations will this year.But Pfizer has other tools at its disposal. The company's anticoagulant Eliquis, cancer medicine Xtandi, as well as its biosimilar business, are meaningfully contributing to its overall performance. Even immunosuppressant Xeljanz could return to growth this yeardespite the regulatory headwinds it encountered last year.Lastly, Pfizer's pipeline includes 29 ongoing phase 3 clinical trials. Expect new products and label expansions to strengthen an already solid lineup.And all of this at a reasonable price, too. Pfizer is trading at just 9.1 times forward earnings compared to an average price-to-earnings ratio of 13.3 for the pharma industry.In short, Pfizer provides a little bit of everything most investors look for: high growth, reasonable value, and stable income in the form of dividends. Too juicy to pass up, indeed.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9004001573,"gmtCreate":1642431803026,"gmtModify":1676533710271,"author":{"id":"4101001888219480","authorId":"4101001888219480","name":"Mengi","avatar":"https://static.tigerbbs.com/268bfe9065ca52180b1b67a30526b2aa","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"4101001888219480","idStr":"4101001888219480"},"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9004001573","repostId":1103076176,"repostType":4,"repost":{"id":"1103076176","pubTimestamp":1642404988,"share":"https://ttm.financial/m/news/1103076176?lang=&edition=fundamental","pubTime":"2022-01-17 15:36","market":"us","language":"en","title":"3 Pharma Stocks With Especially Juicy Dividends","url":"https://stock-news.laohu8.com/highlight/detail?id=1103076176","media":"Motley Fool","summary":"Key PointsAbbVie is a Dividend Aristocrat that also performed quite well over the past year.Gilead S","content":"<html><head></head><body><p>Key Points</p><ul><li>AbbVie is a Dividend Aristocrat that also performed quite well over the past year.</li><li>Gilead Sciences has increased its dividend 51% over the last five years and should keep the streak going in 2022.</li><li>Pfizer is a cash cow with a strong and stable dividend.</li></ul><p>Big pharmaceutical companies usually make big bucks. And many of them return a portion of their profits to investors in the form of dividends.</p><p>We asked three Motley Fool contributors to pick the pharma stocks that they think have especially juicy dividends. Here&#39;s why they chose <a href=\"https://laohu8.com/S/ABBV\"><b>AbbVie</b></a>, <a href=\"https://laohu8.com/S/GILD\"><b>Gilead Sciences</b></a>, and <a href=\"https://laohu8.com/S/PFE\"><b>Pfizer</b></a>.</p><p><b>Keith Speights(</b><a href=\"https://laohu8.com/S/ABBV\"><b>AbbVie</b></a><b>):</b>There&#39;s so much to like about AbbVie&#39;s dividend that it&#39;s hard to know where to begin. But I&#39;ll start with its attractive yield of 4.2%. What&#39;s even better, though, is that AbbVie is a Dividend Aristocrat-- an elite group of <b>S&amp;P 500</b>members that have increased their dividends for at least 25 consecutive years.</p><p>Unlike some dividend stocks, AbbVie has also delivered strong growth lately. Its shares soared 26% last year. With dividends included, the drugmaker&#39;s total return easily beat the S&amp;P 500&#39;s performance.</p><p>There are a couple of concerns for AbbVie, though. The U.S. Food and Drug Administration (FDA) recentlyplaced additional warnings on the company&#39;s JAK inhibitor Rinvoq. This could limit the sales of the drug to some extent. Also, AbbVie&#39;s top-selling drug Humira faces biosimilar rivals in the U.S. beginning in 2023. Sales are expected to decline significantly.</p><p>However, AbbVie&#39;s dividend shouldn&#39;t be threatened at all. The company could also continue generating solid growth in the second half of this decade after the initial impact of Humira losing exclusivity. AbbVie has several other growth drivers, including autoimmune disease drug Skyrizi and blood cancer drug Venclexta.</p><p><b>David Jagielski</b> <b>(</b> <a href=\"https://laohu8.com/S/GILD\"><b>Gilead Sciences</b></a><b>):</b>Investing in a high-yielding dividend stock can be a great way to make the most of your money. But to ensure that inflation isn&#39;t chipping away at that cash flow over time, you&#39;ll also want to invest in a company that raises its dividend payments. With Gilead Sciences, investors are getting the best of both worlds -- a high yield of around 4% that has also been growing over the years.</p><p>Five years ago, Gilead was paying its investors a quarterly dividend of $0.47. Today, those payments are up to $0.71, rising by 51% during that time and averaging a compound annual growth rate of 8.6%. And that already-juicy dividend can get even more mouth-watering as the company&#39;s payout ratio sits below 50%.</p><p>In Gilead&#39;s latest quarterly update, sales rose 13% year over year to $7.4 billion. The company also reported net income of $2.6 billion, which equated to a per-share (diluted) profit of $2.05. And in the nine months leading up to that date, the earnings per share (EPS) topped $4.63. That&#39;s easily enough to cover the current dividend, which on an annual basis would total $2.84. And it leaves room for some generous increases as well.</p><p>Now may be an optimal time to buy Gilead stock. The company typically reports its fourth-quarter earnings in early February. Gilead could announce another dividend hike then as well. Since 2015 when the company began making dividend payments, Gilead has consistently raised its payouts each subsequent year (and normally in February).</p><p>With solid financials and the company likely to continue receiving a boost from its COVID-19 treatment, Veklury, it&#39;s probable that this dividend could get even juicier than it already is today.</p><p><b>Prosper Junior Bakiny(</b><a href=\"https://laohu8.com/S/PFE\"><b>Pfizer</b></a><b>):</b>When it comes to dividend stocks, high yields are great, but the ability to sustain dividend increases is even better. That&#39;s what pharma giant Pfizer provides. The company&#39;s current yield of 2.75% is well above the S&amp;P 500&#39;s average of 1.27%. But just as important is Pfizer&#39;s very conservative cash payout ratio of 29.64%. For context, a payout ratio below the 60% range is generally considered good.</p><p>This implies that Pfizer has considerable room to sustain dividend increases in large part thanks to the cash it has been generating over the past year. Pfizer&#39;s free cash flow soared by 126.1% to $29.2 billion in the trailing twelve-month period. We can attribute that primarily to Pfizer&#39;s COVID-19 vaccine, Comirnaty. This vaccine has become ablockbuster product-- and then some -- in its first year on the market.</p><p>Pfizer said it would generate $36 billion from Comirnaty in the fiscal year 2021. Given recent developments surrounding the pandemic, 2022 should be another excellent year for the vaccine. Management thinks sales of Comirnaty could come in at $29 billion this year. Pfizer&#39;s coronavirus-related business alone, which includes Comirnaty and Paxlovid, a COVID-19 therapy that recently earned authorization, will generate more sales than dozens of large corporations will this year.</p><p>But Pfizer has other tools at its disposal. The company&#39;s anticoagulant Eliquis, cancer medicine Xtandi, as well as its biosimilar business, are meaningfully contributing to its overall performance. Even immunosuppressant Xeljanz could return to growth this yeardespite the regulatory headwinds it encountered last year.</p><p>Lastly, Pfizer&#39;s pipeline includes 29 ongoing phase 3 clinical trials. Expect new products and label expansions to strengthen an already solid lineup.</p><p>And all of this at a reasonable price, too. Pfizer is trading at just 9.1 times forward earnings compared to an average price-to-earnings ratio of 13.3 for the pharma industry.</p><p>In short, Pfizer provides a little bit of everything most investors look for: high growth, reasonable value, and stable income in the form of dividends. Too juicy to pass up, indeed.</p><p></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Pharma Stocks With Especially Juicy Dividends</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Pharma Stocks With Especially Juicy Dividends\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-17 15:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/16/3-pharma-stocks-with-especially-juicy-dividends/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Key PointsAbbVie is a Dividend Aristocrat that also performed quite well over the past year.Gilead Sciences has increased its dividend 51% over the last five years and should keep the streak going in ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/16/3-pharma-stocks-with-especially-juicy-dividends/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GILD":"吉利德科学","ABBV":"艾伯维公司","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2022/01/16/3-pharma-stocks-with-especially-juicy-dividends/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1103076176","content_text":"Key PointsAbbVie is a Dividend Aristocrat that also performed quite well over the past year.Gilead Sciences has increased its dividend 51% over the last five years and should keep the streak going in 2022.Pfizer is a cash cow with a strong and stable dividend.Big pharmaceutical companies usually make big bucks. And many of them return a portion of their profits to investors in the form of dividends.We asked three Motley Fool contributors to pick the pharma stocks that they think have especially juicy dividends. Here's why they chose AbbVie, Gilead Sciences, and Pfizer.Keith Speights(AbbVie):There's so much to like about AbbVie's dividend that it's hard to know where to begin. But I'll start with its attractive yield of 4.2%. What's even better, though, is that AbbVie is a Dividend Aristocrat-- an elite group of S&P 500members that have increased their dividends for at least 25 consecutive years.Unlike some dividend stocks, AbbVie has also delivered strong growth lately. Its shares soared 26% last year. With dividends included, the drugmaker's total return easily beat the S&P 500's performance.There are a couple of concerns for AbbVie, though. The U.S. Food and Drug Administration (FDA) recentlyplaced additional warnings on the company's JAK inhibitor Rinvoq. This could limit the sales of the drug to some extent. Also, AbbVie's top-selling drug Humira faces biosimilar rivals in the U.S. beginning in 2023. Sales are expected to decline significantly.However, AbbVie's dividend shouldn't be threatened at all. The company could also continue generating solid growth in the second half of this decade after the initial impact of Humira losing exclusivity. AbbVie has several other growth drivers, including autoimmune disease drug Skyrizi and blood cancer drug Venclexta.David Jagielski ( Gilead Sciences):Investing in a high-yielding dividend stock can be a great way to make the most of your money. But to ensure that inflation isn't chipping away at that cash flow over time, you'll also want to invest in a company that raises its dividend payments. With Gilead Sciences, investors are getting the best of both worlds -- a high yield of around 4% that has also been growing over the years.Five years ago, Gilead was paying its investors a quarterly dividend of $0.47. Today, those payments are up to $0.71, rising by 51% during that time and averaging a compound annual growth rate of 8.6%. And that already-juicy dividend can get even more mouth-watering as the company's payout ratio sits below 50%.In Gilead's latest quarterly update, sales rose 13% year over year to $7.4 billion. The company also reported net income of $2.6 billion, which equated to a per-share (diluted) profit of $2.05. And in the nine months leading up to that date, the earnings per share (EPS) topped $4.63. That's easily enough to cover the current dividend, which on an annual basis would total $2.84. And it leaves room for some generous increases as well.Now may be an optimal time to buy Gilead stock. The company typically reports its fourth-quarter earnings in early February. Gilead could announce another dividend hike then as well. Since 2015 when the company began making dividend payments, Gilead has consistently raised its payouts each subsequent year (and normally in February).With solid financials and the company likely to continue receiving a boost from its COVID-19 treatment, Veklury, it's probable that this dividend could get even juicier than it already is today.Prosper Junior Bakiny(Pfizer):When it comes to dividend stocks, high yields are great, but the ability to sustain dividend increases is even better. That's what pharma giant Pfizer provides. The company's current yield of 2.75% is well above the S&P 500's average of 1.27%. But just as important is Pfizer's very conservative cash payout ratio of 29.64%. For context, a payout ratio below the 60% range is generally considered good.This implies that Pfizer has considerable room to sustain dividend increases in large part thanks to the cash it has been generating over the past year. Pfizer's free cash flow soared by 126.1% to $29.2 billion in the trailing twelve-month period. We can attribute that primarily to Pfizer's COVID-19 vaccine, Comirnaty. This vaccine has become ablockbuster product-- and then some -- in its first year on the market.Pfizer said it would generate $36 billion from Comirnaty in the fiscal year 2021. Given recent developments surrounding the pandemic, 2022 should be another excellent year for the vaccine. Management thinks sales of Comirnaty could come in at $29 billion this year. Pfizer's coronavirus-related business alone, which includes Comirnaty and Paxlovid, a COVID-19 therapy that recently earned authorization, will generate more sales than dozens of large corporations will this year.But Pfizer has other tools at its disposal. The company's anticoagulant Eliquis, cancer medicine Xtandi, as well as its biosimilar business, are meaningfully contributing to its overall performance. Even immunosuppressant Xeljanz could return to growth this yeardespite the regulatory headwinds it encountered last year.Lastly, Pfizer's pipeline includes 29 ongoing phase 3 clinical trials. Expect new products and label expansions to strengthen an already solid lineup.And all of this at a reasonable price, too. Pfizer is trading at just 9.1 times forward earnings compared to an average price-to-earnings ratio of 13.3 for the pharma industry.In short, Pfizer provides a little bit of everything most investors look for: high growth, reasonable value, and stable income in the form of dividends. Too juicy to pass up, indeed.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9005744079,"gmtCreate":1642428039513,"gmtModify":1676533709859,"author":{"id":"3577755293052640","authorId":"3577755293052640","name":"SK19","avatar":"https://static.tigerbbs.com/ee6b25332525b16399562f21677fa1cd","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3577755293052640","idStr":"3577755293052640"},"htmlText":"AbbVie 💪💪💪","listText":"AbbVie 💪💪💪","text":"AbbVie 💪💪💪","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9005744079","repostId":1103076176,"repostType":4,"repost":{"id":"1103076176","pubTimestamp":1642404988,"share":"https://ttm.financial/m/news/1103076176?lang=&edition=fundamental","pubTime":"2022-01-17 15:36","market":"us","language":"en","title":"3 Pharma Stocks With Especially Juicy Dividends","url":"https://stock-news.laohu8.com/highlight/detail?id=1103076176","media":"Motley Fool","summary":"Key PointsAbbVie is a Dividend Aristocrat that also performed quite well over the past year.Gilead S","content":"<html><head></head><body><p>Key Points</p><ul><li>AbbVie is a Dividend Aristocrat that also performed quite well over the past year.</li><li>Gilead Sciences has increased its dividend 51% over the last five years and should keep the streak going in 2022.</li><li>Pfizer is a cash cow with a strong and stable dividend.</li></ul><p>Big pharmaceutical companies usually make big bucks. And many of them return a portion of their profits to investors in the form of dividends.</p><p>We asked three Motley Fool contributors to pick the pharma stocks that they think have especially juicy dividends. Here&#39;s why they chose <a href=\"https://laohu8.com/S/ABBV\"><b>AbbVie</b></a>, <a href=\"https://laohu8.com/S/GILD\"><b>Gilead Sciences</b></a>, and <a href=\"https://laohu8.com/S/PFE\"><b>Pfizer</b></a>.</p><p><b>Keith Speights(</b><a href=\"https://laohu8.com/S/ABBV\"><b>AbbVie</b></a><b>):</b>There&#39;s so much to like about AbbVie&#39;s dividend that it&#39;s hard to know where to begin. But I&#39;ll start with its attractive yield of 4.2%. What&#39;s even better, though, is that AbbVie is a Dividend Aristocrat-- an elite group of <b>S&amp;P 500</b>members that have increased their dividends for at least 25 consecutive years.</p><p>Unlike some dividend stocks, AbbVie has also delivered strong growth lately. Its shares soared 26% last year. With dividends included, the drugmaker&#39;s total return easily beat the S&amp;P 500&#39;s performance.</p><p>There are a couple of concerns for AbbVie, though. The U.S. Food and Drug Administration (FDA) recentlyplaced additional warnings on the company&#39;s JAK inhibitor Rinvoq. This could limit the sales of the drug to some extent. Also, AbbVie&#39;s top-selling drug Humira faces biosimilar rivals in the U.S. beginning in 2023. Sales are expected to decline significantly.</p><p>However, AbbVie&#39;s dividend shouldn&#39;t be threatened at all. The company could also continue generating solid growth in the second half of this decade after the initial impact of Humira losing exclusivity. AbbVie has several other growth drivers, including autoimmune disease drug Skyrizi and blood cancer drug Venclexta.</p><p><b>David Jagielski</b> <b>(</b> <a href=\"https://laohu8.com/S/GILD\"><b>Gilead Sciences</b></a><b>):</b>Investing in a high-yielding dividend stock can be a great way to make the most of your money. But to ensure that inflation isn&#39;t chipping away at that cash flow over time, you&#39;ll also want to invest in a company that raises its dividend payments. With Gilead Sciences, investors are getting the best of both worlds -- a high yield of around 4% that has also been growing over the years.</p><p>Five years ago, Gilead was paying its investors a quarterly dividend of $0.47. Today, those payments are up to $0.71, rising by 51% during that time and averaging a compound annual growth rate of 8.6%. And that already-juicy dividend can get even more mouth-watering as the company&#39;s payout ratio sits below 50%.</p><p>In Gilead&#39;s latest quarterly update, sales rose 13% year over year to $7.4 billion. The company also reported net income of $2.6 billion, which equated to a per-share (diluted) profit of $2.05. And in the nine months leading up to that date, the earnings per share (EPS) topped $4.63. That&#39;s easily enough to cover the current dividend, which on an annual basis would total $2.84. And it leaves room for some generous increases as well.</p><p>Now may be an optimal time to buy Gilead stock. The company typically reports its fourth-quarter earnings in early February. Gilead could announce another dividend hike then as well. Since 2015 when the company began making dividend payments, Gilead has consistently raised its payouts each subsequent year (and normally in February).</p><p>With solid financials and the company likely to continue receiving a boost from its COVID-19 treatment, Veklury, it&#39;s probable that this dividend could get even juicier than it already is today.</p><p><b>Prosper Junior Bakiny(</b><a href=\"https://laohu8.com/S/PFE\"><b>Pfizer</b></a><b>):</b>When it comes to dividend stocks, high yields are great, but the ability to sustain dividend increases is even better. That&#39;s what pharma giant Pfizer provides. The company&#39;s current yield of 2.75% is well above the S&amp;P 500&#39;s average of 1.27%. But just as important is Pfizer&#39;s very conservative cash payout ratio of 29.64%. For context, a payout ratio below the 60% range is generally considered good.</p><p>This implies that Pfizer has considerable room to sustain dividend increases in large part thanks to the cash it has been generating over the past year. Pfizer&#39;s free cash flow soared by 126.1% to $29.2 billion in the trailing twelve-month period. We can attribute that primarily to Pfizer&#39;s COVID-19 vaccine, Comirnaty. This vaccine has become ablockbuster product-- and then some -- in its first year on the market.</p><p>Pfizer said it would generate $36 billion from Comirnaty in the fiscal year 2021. Given recent developments surrounding the pandemic, 2022 should be another excellent year for the vaccine. Management thinks sales of Comirnaty could come in at $29 billion this year. Pfizer&#39;s coronavirus-related business alone, which includes Comirnaty and Paxlovid, a COVID-19 therapy that recently earned authorization, will generate more sales than dozens of large corporations will this year.</p><p>But Pfizer has other tools at its disposal. The company&#39;s anticoagulant Eliquis, cancer medicine Xtandi, as well as its biosimilar business, are meaningfully contributing to its overall performance. Even immunosuppressant Xeljanz could return to growth this yeardespite the regulatory headwinds it encountered last year.</p><p>Lastly, Pfizer&#39;s pipeline includes 29 ongoing phase 3 clinical trials. Expect new products and label expansions to strengthen an already solid lineup.</p><p>And all of this at a reasonable price, too. Pfizer is trading at just 9.1 times forward earnings compared to an average price-to-earnings ratio of 13.3 for the pharma industry.</p><p>In short, Pfizer provides a little bit of everything most investors look for: high growth, reasonable value, and stable income in the form of dividends. Too juicy to pass up, indeed.</p><p></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Pharma Stocks With Especially Juicy Dividends</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Pharma Stocks With Especially Juicy Dividends\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-17 15:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/16/3-pharma-stocks-with-especially-juicy-dividends/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Key PointsAbbVie is a Dividend Aristocrat that also performed quite well over the past year.Gilead Sciences has increased its dividend 51% over the last five years and should keep the streak going in ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/16/3-pharma-stocks-with-especially-juicy-dividends/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GILD":"吉利德科学","ABBV":"艾伯维公司","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2022/01/16/3-pharma-stocks-with-especially-juicy-dividends/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1103076176","content_text":"Key PointsAbbVie is a Dividend Aristocrat that also performed quite well over the past year.Gilead Sciences has increased its dividend 51% over the last five years and should keep the streak going in 2022.Pfizer is a cash cow with a strong and stable dividend.Big pharmaceutical companies usually make big bucks. And many of them return a portion of their profits to investors in the form of dividends.We asked three Motley Fool contributors to pick the pharma stocks that they think have especially juicy dividends. Here's why they chose AbbVie, Gilead Sciences, and Pfizer.Keith Speights(AbbVie):There's so much to like about AbbVie's dividend that it's hard to know where to begin. But I'll start with its attractive yield of 4.2%. What's even better, though, is that AbbVie is a Dividend Aristocrat-- an elite group of S&P 500members that have increased their dividends for at least 25 consecutive years.Unlike some dividend stocks, AbbVie has also delivered strong growth lately. Its shares soared 26% last year. With dividends included, the drugmaker's total return easily beat the S&P 500's performance.There are a couple of concerns for AbbVie, though. The U.S. Food and Drug Administration (FDA) recentlyplaced additional warnings on the company's JAK inhibitor Rinvoq. This could limit the sales of the drug to some extent. Also, AbbVie's top-selling drug Humira faces biosimilar rivals in the U.S. beginning in 2023. Sales are expected to decline significantly.However, AbbVie's dividend shouldn't be threatened at all. The company could also continue generating solid growth in the second half of this decade after the initial impact of Humira losing exclusivity. AbbVie has several other growth drivers, including autoimmune disease drug Skyrizi and blood cancer drug Venclexta.David Jagielski ( Gilead Sciences):Investing in a high-yielding dividend stock can be a great way to make the most of your money. But to ensure that inflation isn't chipping away at that cash flow over time, you'll also want to invest in a company that raises its dividend payments. With Gilead Sciences, investors are getting the best of both worlds -- a high yield of around 4% that has also been growing over the years.Five years ago, Gilead was paying its investors a quarterly dividend of $0.47. Today, those payments are up to $0.71, rising by 51% during that time and averaging a compound annual growth rate of 8.6%. And that already-juicy dividend can get even more mouth-watering as the company's payout ratio sits below 50%.In Gilead's latest quarterly update, sales rose 13% year over year to $7.4 billion. The company also reported net income of $2.6 billion, which equated to a per-share (diluted) profit of $2.05. And in the nine months leading up to that date, the earnings per share (EPS) topped $4.63. That's easily enough to cover the current dividend, which on an annual basis would total $2.84. And it leaves room for some generous increases as well.Now may be an optimal time to buy Gilead stock. The company typically reports its fourth-quarter earnings in early February. Gilead could announce another dividend hike then as well. Since 2015 when the company began making dividend payments, Gilead has consistently raised its payouts each subsequent year (and normally in February).With solid financials and the company likely to continue receiving a boost from its COVID-19 treatment, Veklury, it's probable that this dividend could get even juicier than it already is today.Prosper Junior Bakiny(Pfizer):When it comes to dividend stocks, high yields are great, but the ability to sustain dividend increases is even better. That's what pharma giant Pfizer provides. The company's current yield of 2.75% is well above the S&P 500's average of 1.27%. But just as important is Pfizer's very conservative cash payout ratio of 29.64%. For context, a payout ratio below the 60% range is generally considered good.This implies that Pfizer has considerable room to sustain dividend increases in large part thanks to the cash it has been generating over the past year. Pfizer's free cash flow soared by 126.1% to $29.2 billion in the trailing twelve-month period. We can attribute that primarily to Pfizer's COVID-19 vaccine, Comirnaty. This vaccine has become ablockbuster product-- and then some -- in its first year on the market.Pfizer said it would generate $36 billion from Comirnaty in the fiscal year 2021. Given recent developments surrounding the pandemic, 2022 should be another excellent year for the vaccine. Management thinks sales of Comirnaty could come in at $29 billion this year. Pfizer's coronavirus-related business alone, which includes Comirnaty and Paxlovid, a COVID-19 therapy that recently earned authorization, will generate more sales than dozens of large corporations will this year.But Pfizer has other tools at its disposal. The company's anticoagulant Eliquis, cancer medicine Xtandi, as well as its biosimilar business, are meaningfully contributing to its overall performance. Even immunosuppressant Xeljanz could return to growth this yeardespite the regulatory headwinds it encountered last year.Lastly, Pfizer's pipeline includes 29 ongoing phase 3 clinical trials. Expect new products and label expansions to strengthen an already solid lineup.And all of this at a reasonable price, too. Pfizer is trading at just 9.1 times forward earnings compared to an average price-to-earnings ratio of 13.3 for the pharma industry.In short, Pfizer provides a little bit of everything most investors look for: high growth, reasonable value, and stable income in the form of dividends. Too juicy to pass up, indeed.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9005748255,"gmtCreate":1642426922913,"gmtModify":1676533709719,"author":{"id":"3565260704760850","authorId":"3565260704760850","name":"Svkartik","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":7,"crmLevelSwitch":0,"authorIdStr":"3565260704760850","idStr":"3565260704760850"},"htmlText":"Juicy only for US residentsFor us, we clearly lose by paying 30% dividend withholding taxes - this is is something most investors turn a blind eye to buy over time it will significantly eat into total shareholder returns&nbsp;US dividend stocks are for trading and not great for Long term for non US residents&nbsp;","listText":"Juicy only for US residentsFor us, we clearly lose by paying 30% dividend withholding taxes - this is is something most investors turn a blind eye to buy over time it will significantly eat into total shareholder returns&nbsp;US dividend stocks are for trading and not great for Long term for non US residents&nbsp;","text":"Juicy only for US residentsFor us, we clearly lose by paying 30% dividend withholding taxes - this is is something most investors turn a blind eye to buy over time it will significantly eat into total shareholder returns US dividend stocks are for trading and not great for Long term for non US residents","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9005748255","repostId":1103076176,"repostType":4,"repost":{"id":"1103076176","pubTimestamp":1642404988,"share":"https://ttm.financial/m/news/1103076176?lang=&edition=fundamental","pubTime":"2022-01-17 15:36","market":"us","language":"en","title":"3 Pharma Stocks With Especially Juicy Dividends","url":"https://stock-news.laohu8.com/highlight/detail?id=1103076176","media":"Motley Fool","summary":"Key PointsAbbVie is a Dividend Aristocrat that also performed quite well over the past year.Gilead S","content":"<html><head></head><body><p>Key Points</p><ul><li>AbbVie is a Dividend Aristocrat that also performed quite well over the past year.</li><li>Gilead Sciences has increased its dividend 51% over the last five years and should keep the streak going in 2022.</li><li>Pfizer is a cash cow with a strong and stable dividend.</li></ul><p>Big pharmaceutical companies usually make big bucks. And many of them return a portion of their profits to investors in the form of dividends.</p><p>We asked three Motley Fool contributors to pick the pharma stocks that they think have especially juicy dividends. Here&#39;s why they chose <a href=\"https://laohu8.com/S/ABBV\"><b>AbbVie</b></a>, <a href=\"https://laohu8.com/S/GILD\"><b>Gilead Sciences</b></a>, and <a href=\"https://laohu8.com/S/PFE\"><b>Pfizer</b></a>.</p><p><b>Keith Speights(</b><a href=\"https://laohu8.com/S/ABBV\"><b>AbbVie</b></a><b>):</b>There&#39;s so much to like about AbbVie&#39;s dividend that it&#39;s hard to know where to begin. But I&#39;ll start with its attractive yield of 4.2%. What&#39;s even better, though, is that AbbVie is a Dividend Aristocrat-- an elite group of <b>S&amp;P 500</b>members that have increased their dividends for at least 25 consecutive years.</p><p>Unlike some dividend stocks, AbbVie has also delivered strong growth lately. Its shares soared 26% last year. With dividends included, the drugmaker&#39;s total return easily beat the S&amp;P 500&#39;s performance.</p><p>There are a couple of concerns for AbbVie, though. The U.S. Food and Drug Administration (FDA) recentlyplaced additional warnings on the company&#39;s JAK inhibitor Rinvoq. This could limit the sales of the drug to some extent. Also, AbbVie&#39;s top-selling drug Humira faces biosimilar rivals in the U.S. beginning in 2023. Sales are expected to decline significantly.</p><p>However, AbbVie&#39;s dividend shouldn&#39;t be threatened at all. The company could also continue generating solid growth in the second half of this decade after the initial impact of Humira losing exclusivity. AbbVie has several other growth drivers, including autoimmune disease drug Skyrizi and blood cancer drug Venclexta.</p><p><b>David Jagielski</b> <b>(</b> <a href=\"https://laohu8.com/S/GILD\"><b>Gilead Sciences</b></a><b>):</b>Investing in a high-yielding dividend stock can be a great way to make the most of your money. But to ensure that inflation isn&#39;t chipping away at that cash flow over time, you&#39;ll also want to invest in a company that raises its dividend payments. With Gilead Sciences, investors are getting the best of both worlds -- a high yield of around 4% that has also been growing over the years.</p><p>Five years ago, Gilead was paying its investors a quarterly dividend of $0.47. Today, those payments are up to $0.71, rising by 51% during that time and averaging a compound annual growth rate of 8.6%. And that already-juicy dividend can get even more mouth-watering as the company&#39;s payout ratio sits below 50%.</p><p>In Gilead&#39;s latest quarterly update, sales rose 13% year over year to $7.4 billion. The company also reported net income of $2.6 billion, which equated to a per-share (diluted) profit of $2.05. And in the nine months leading up to that date, the earnings per share (EPS) topped $4.63. That&#39;s easily enough to cover the current dividend, which on an annual basis would total $2.84. And it leaves room for some generous increases as well.</p><p>Now may be an optimal time to buy Gilead stock. The company typically reports its fourth-quarter earnings in early February. Gilead could announce another dividend hike then as well. Since 2015 when the company began making dividend payments, Gilead has consistently raised its payouts each subsequent year (and normally in February).</p><p>With solid financials and the company likely to continue receiving a boost from its COVID-19 treatment, Veklury, it&#39;s probable that this dividend could get even juicier than it already is today.</p><p><b>Prosper Junior Bakiny(</b><a href=\"https://laohu8.com/S/PFE\"><b>Pfizer</b></a><b>):</b>When it comes to dividend stocks, high yields are great, but the ability to sustain dividend increases is even better. That&#39;s what pharma giant Pfizer provides. The company&#39;s current yield of 2.75% is well above the S&amp;P 500&#39;s average of 1.27%. But just as important is Pfizer&#39;s very conservative cash payout ratio of 29.64%. For context, a payout ratio below the 60% range is generally considered good.</p><p>This implies that Pfizer has considerable room to sustain dividend increases in large part thanks to the cash it has been generating over the past year. Pfizer&#39;s free cash flow soared by 126.1% to $29.2 billion in the trailing twelve-month period. We can attribute that primarily to Pfizer&#39;s COVID-19 vaccine, Comirnaty. This vaccine has become ablockbuster product-- and then some -- in its first year on the market.</p><p>Pfizer said it would generate $36 billion from Comirnaty in the fiscal year 2021. Given recent developments surrounding the pandemic, 2022 should be another excellent year for the vaccine. Management thinks sales of Comirnaty could come in at $29 billion this year. Pfizer&#39;s coronavirus-related business alone, which includes Comirnaty and Paxlovid, a COVID-19 therapy that recently earned authorization, will generate more sales than dozens of large corporations will this year.</p><p>But Pfizer has other tools at its disposal. The company&#39;s anticoagulant Eliquis, cancer medicine Xtandi, as well as its biosimilar business, are meaningfully contributing to its overall performance. Even immunosuppressant Xeljanz could return to growth this yeardespite the regulatory headwinds it encountered last year.</p><p>Lastly, Pfizer&#39;s pipeline includes 29 ongoing phase 3 clinical trials. Expect new products and label expansions to strengthen an already solid lineup.</p><p>And all of this at a reasonable price, too. Pfizer is trading at just 9.1 times forward earnings compared to an average price-to-earnings ratio of 13.3 for the pharma industry.</p><p>In short, Pfizer provides a little bit of everything most investors look for: high growth, reasonable value, and stable income in the form of dividends. Too juicy to pass up, indeed.</p><p></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Pharma Stocks With Especially Juicy Dividends</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Pharma Stocks With Especially Juicy Dividends\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-17 15:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/16/3-pharma-stocks-with-especially-juicy-dividends/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Key PointsAbbVie is a Dividend Aristocrat that also performed quite well over the past year.Gilead Sciences has increased its dividend 51% over the last five years and should keep the streak going in ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/16/3-pharma-stocks-with-especially-juicy-dividends/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GILD":"吉利德科学","ABBV":"艾伯维公司","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2022/01/16/3-pharma-stocks-with-especially-juicy-dividends/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1103076176","content_text":"Key PointsAbbVie is a Dividend Aristocrat that also performed quite well over the past year.Gilead Sciences has increased its dividend 51% over the last five years and should keep the streak going in 2022.Pfizer is a cash cow with a strong and stable dividend.Big pharmaceutical companies usually make big bucks. And many of them return a portion of their profits to investors in the form of dividends.We asked three Motley Fool contributors to pick the pharma stocks that they think have especially juicy dividends. Here's why they chose AbbVie, Gilead Sciences, and Pfizer.Keith Speights(AbbVie):There's so much to like about AbbVie's dividend that it's hard to know where to begin. But I'll start with its attractive yield of 4.2%. What's even better, though, is that AbbVie is a Dividend Aristocrat-- an elite group of S&P 500members that have increased their dividends for at least 25 consecutive years.Unlike some dividend stocks, AbbVie has also delivered strong growth lately. Its shares soared 26% last year. With dividends included, the drugmaker's total return easily beat the S&P 500's performance.There are a couple of concerns for AbbVie, though. The U.S. Food and Drug Administration (FDA) recentlyplaced additional warnings on the company's JAK inhibitor Rinvoq. This could limit the sales of the drug to some extent. Also, AbbVie's top-selling drug Humira faces biosimilar rivals in the U.S. beginning in 2023. Sales are expected to decline significantly.However, AbbVie's dividend shouldn't be threatened at all. The company could also continue generating solid growth in the second half of this decade after the initial impact of Humira losing exclusivity. AbbVie has several other growth drivers, including autoimmune disease drug Skyrizi and blood cancer drug Venclexta.David Jagielski ( Gilead Sciences):Investing in a high-yielding dividend stock can be a great way to make the most of your money. But to ensure that inflation isn't chipping away at that cash flow over time, you'll also want to invest in a company that raises its dividend payments. With Gilead Sciences, investors are getting the best of both worlds -- a high yield of around 4% that has also been growing over the years.Five years ago, Gilead was paying its investors a quarterly dividend of $0.47. Today, those payments are up to $0.71, rising by 51% during that time and averaging a compound annual growth rate of 8.6%. And that already-juicy dividend can get even more mouth-watering as the company's payout ratio sits below 50%.In Gilead's latest quarterly update, sales rose 13% year over year to $7.4 billion. The company also reported net income of $2.6 billion, which equated to a per-share (diluted) profit of $2.05. And in the nine months leading up to that date, the earnings per share (EPS) topped $4.63. That's easily enough to cover the current dividend, which on an annual basis would total $2.84. And it leaves room for some generous increases as well.Now may be an optimal time to buy Gilead stock. The company typically reports its fourth-quarter earnings in early February. Gilead could announce another dividend hike then as well. Since 2015 when the company began making dividend payments, Gilead has consistently raised its payouts each subsequent year (and normally in February).With solid financials and the company likely to continue receiving a boost from its COVID-19 treatment, Veklury, it's probable that this dividend could get even juicier than it already is today.Prosper Junior Bakiny(Pfizer):When it comes to dividend stocks, high yields are great, but the ability to sustain dividend increases is even better. That's what pharma giant Pfizer provides. The company's current yield of 2.75% is well above the S&P 500's average of 1.27%. But just as important is Pfizer's very conservative cash payout ratio of 29.64%. For context, a payout ratio below the 60% range is generally considered good.This implies that Pfizer has considerable room to sustain dividend increases in large part thanks to the cash it has been generating over the past year. Pfizer's free cash flow soared by 126.1% to $29.2 billion in the trailing twelve-month period. We can attribute that primarily to Pfizer's COVID-19 vaccine, Comirnaty. This vaccine has become ablockbuster product-- and then some -- in its first year on the market.Pfizer said it would generate $36 billion from Comirnaty in the fiscal year 2021. Given recent developments surrounding the pandemic, 2022 should be another excellent year for the vaccine. Management thinks sales of Comirnaty could come in at $29 billion this year. Pfizer's coronavirus-related business alone, which includes Comirnaty and Paxlovid, a COVID-19 therapy that recently earned authorization, will generate more sales than dozens of large corporations will this year.But Pfizer has other tools at its disposal. The company's anticoagulant Eliquis, cancer medicine Xtandi, as well as its biosimilar business, are meaningfully contributing to its overall performance. Even immunosuppressant Xeljanz could return to growth this yeardespite the regulatory headwinds it encountered last year.Lastly, Pfizer's pipeline includes 29 ongoing phase 3 clinical trials. Expect new products and label expansions to strengthen an already solid lineup.And all of this at a reasonable price, too. Pfizer is trading at just 9.1 times forward earnings compared to an average price-to-earnings ratio of 13.3 for the pharma industry.In short, Pfizer provides a little bit of everything most investors look for: high growth, reasonable value, and stable income in the form of dividends. Too juicy to pass up, indeed.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9005755964,"gmtCreate":1642424682615,"gmtModify":1676533709556,"author":{"id":"4099126036711530","authorId":"4099126036711530","name":"LCare Trader","avatar":"https://static.tigerbbs.com/ef5791162e4724ba08e570bfc4bd79fd","vip":1,"crmLevel":3,"crmLevelSwitch":0,"authorIdStr":"4099126036711530","idStr":"4099126036711530"},"htmlText":"Super liked","listText":"Super liked","text":"Super liked","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9005755964","repostId":1103076176,"repostType":4,"repost":{"id":"1103076176","pubTimestamp":1642404988,"share":"https://ttm.financial/m/news/1103076176?lang=&edition=fundamental","pubTime":"2022-01-17 15:36","market":"us","language":"en","title":"3 Pharma Stocks With Especially Juicy Dividends","url":"https://stock-news.laohu8.com/highlight/detail?id=1103076176","media":"Motley Fool","summary":"Key PointsAbbVie is a Dividend Aristocrat that also performed quite well over the past year.Gilead S","content":"<html><head></head><body><p>Key Points</p><ul><li>AbbVie is a Dividend Aristocrat that also performed quite well over the past year.</li><li>Gilead Sciences has increased its dividend 51% over the last five years and should keep the streak going in 2022.</li><li>Pfizer is a cash cow with a strong and stable dividend.</li></ul><p>Big pharmaceutical companies usually make big bucks. And many of them return a portion of their profits to investors in the form of dividends.</p><p>We asked three Motley Fool contributors to pick the pharma stocks that they think have especially juicy dividends. Here&#39;s why they chose <a href=\"https://laohu8.com/S/ABBV\"><b>AbbVie</b></a>, <a href=\"https://laohu8.com/S/GILD\"><b>Gilead Sciences</b></a>, and <a href=\"https://laohu8.com/S/PFE\"><b>Pfizer</b></a>.</p><p><b>Keith Speights(</b><a href=\"https://laohu8.com/S/ABBV\"><b>AbbVie</b></a><b>):</b>There&#39;s so much to like about AbbVie&#39;s dividend that it&#39;s hard to know where to begin. But I&#39;ll start with its attractive yield of 4.2%. What&#39;s even better, though, is that AbbVie is a Dividend Aristocrat-- an elite group of <b>S&amp;P 500</b>members that have increased their dividends for at least 25 consecutive years.</p><p>Unlike some dividend stocks, AbbVie has also delivered strong growth lately. Its shares soared 26% last year. With dividends included, the drugmaker&#39;s total return easily beat the S&amp;P 500&#39;s performance.</p><p>There are a couple of concerns for AbbVie, though. The U.S. Food and Drug Administration (FDA) recentlyplaced additional warnings on the company&#39;s JAK inhibitor Rinvoq. This could limit the sales of the drug to some extent. Also, AbbVie&#39;s top-selling drug Humira faces biosimilar rivals in the U.S. beginning in 2023. Sales are expected to decline significantly.</p><p>However, AbbVie&#39;s dividend shouldn&#39;t be threatened at all. The company could also continue generating solid growth in the second half of this decade after the initial impact of Humira losing exclusivity. AbbVie has several other growth drivers, including autoimmune disease drug Skyrizi and blood cancer drug Venclexta.</p><p><b>David Jagielski</b> <b>(</b> <a href=\"https://laohu8.com/S/GILD\"><b>Gilead Sciences</b></a><b>):</b>Investing in a high-yielding dividend stock can be a great way to make the most of your money. But to ensure that inflation isn&#39;t chipping away at that cash flow over time, you&#39;ll also want to invest in a company that raises its dividend payments. With Gilead Sciences, investors are getting the best of both worlds -- a high yield of around 4% that has also been growing over the years.</p><p>Five years ago, Gilead was paying its investors a quarterly dividend of $0.47. Today, those payments are up to $0.71, rising by 51% during that time and averaging a compound annual growth rate of 8.6%. And that already-juicy dividend can get even more mouth-watering as the company&#39;s payout ratio sits below 50%.</p><p>In Gilead&#39;s latest quarterly update, sales rose 13% year over year to $7.4 billion. The company also reported net income of $2.6 billion, which equated to a per-share (diluted) profit of $2.05. And in the nine months leading up to that date, the earnings per share (EPS) topped $4.63. That&#39;s easily enough to cover the current dividend, which on an annual basis would total $2.84. And it leaves room for some generous increases as well.</p><p>Now may be an optimal time to buy Gilead stock. The company typically reports its fourth-quarter earnings in early February. Gilead could announce another dividend hike then as well. Since 2015 when the company began making dividend payments, Gilead has consistently raised its payouts each subsequent year (and normally in February).</p><p>With solid financials and the company likely to continue receiving a boost from its COVID-19 treatment, Veklury, it&#39;s probable that this dividend could get even juicier than it already is today.</p><p><b>Prosper Junior Bakiny(</b><a href=\"https://laohu8.com/S/PFE\"><b>Pfizer</b></a><b>):</b>When it comes to dividend stocks, high yields are great, but the ability to sustain dividend increases is even better. That&#39;s what pharma giant Pfizer provides. The company&#39;s current yield of 2.75% is well above the S&amp;P 500&#39;s average of 1.27%. But just as important is Pfizer&#39;s very conservative cash payout ratio of 29.64%. For context, a payout ratio below the 60% range is generally considered good.</p><p>This implies that Pfizer has considerable room to sustain dividend increases in large part thanks to the cash it has been generating over the past year. Pfizer&#39;s free cash flow soared by 126.1% to $29.2 billion in the trailing twelve-month period. We can attribute that primarily to Pfizer&#39;s COVID-19 vaccine, Comirnaty. This vaccine has become ablockbuster product-- and then some -- in its first year on the market.</p><p>Pfizer said it would generate $36 billion from Comirnaty in the fiscal year 2021. Given recent developments surrounding the pandemic, 2022 should be another excellent year for the vaccine. Management thinks sales of Comirnaty could come in at $29 billion this year. Pfizer&#39;s coronavirus-related business alone, which includes Comirnaty and Paxlovid, a COVID-19 therapy that recently earned authorization, will generate more sales than dozens of large corporations will this year.</p><p>But Pfizer has other tools at its disposal. The company&#39;s anticoagulant Eliquis, cancer medicine Xtandi, as well as its biosimilar business, are meaningfully contributing to its overall performance. Even immunosuppressant Xeljanz could return to growth this yeardespite the regulatory headwinds it encountered last year.</p><p>Lastly, Pfizer&#39;s pipeline includes 29 ongoing phase 3 clinical trials. Expect new products and label expansions to strengthen an already solid lineup.</p><p>And all of this at a reasonable price, too. Pfizer is trading at just 9.1 times forward earnings compared to an average price-to-earnings ratio of 13.3 for the pharma industry.</p><p>In short, Pfizer provides a little bit of everything most investors look for: high growth, reasonable value, and stable income in the form of dividends. Too juicy to pass up, indeed.</p><p></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Pharma Stocks With Especially Juicy Dividends</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Pharma Stocks With Especially Juicy Dividends\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-17 15:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/16/3-pharma-stocks-with-especially-juicy-dividends/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Key PointsAbbVie is a Dividend Aristocrat that also performed quite well over the past year.Gilead Sciences has increased its dividend 51% over the last five years and should keep the streak going in ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/16/3-pharma-stocks-with-especially-juicy-dividends/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GILD":"吉利德科学","ABBV":"艾伯维公司","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2022/01/16/3-pharma-stocks-with-especially-juicy-dividends/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1103076176","content_text":"Key PointsAbbVie is a Dividend Aristocrat that also performed quite well over the past year.Gilead Sciences has increased its dividend 51% over the last five years and should keep the streak going in 2022.Pfizer is a cash cow with a strong and stable dividend.Big pharmaceutical companies usually make big bucks. And many of them return a portion of their profits to investors in the form of dividends.We asked three Motley Fool contributors to pick the pharma stocks that they think have especially juicy dividends. Here's why they chose AbbVie, Gilead Sciences, and Pfizer.Keith Speights(AbbVie):There's so much to like about AbbVie's dividend that it's hard to know where to begin. But I'll start with its attractive yield of 4.2%. What's even better, though, is that AbbVie is a Dividend Aristocrat-- an elite group of S&P 500members that have increased their dividends for at least 25 consecutive years.Unlike some dividend stocks, AbbVie has also delivered strong growth lately. Its shares soared 26% last year. With dividends included, the drugmaker's total return easily beat the S&P 500's performance.There are a couple of concerns for AbbVie, though. The U.S. Food and Drug Administration (FDA) recentlyplaced additional warnings on the company's JAK inhibitor Rinvoq. This could limit the sales of the drug to some extent. Also, AbbVie's top-selling drug Humira faces biosimilar rivals in the U.S. beginning in 2023. Sales are expected to decline significantly.However, AbbVie's dividend shouldn't be threatened at all. The company could also continue generating solid growth in the second half of this decade after the initial impact of Humira losing exclusivity. AbbVie has several other growth drivers, including autoimmune disease drug Skyrizi and blood cancer drug Venclexta.David Jagielski ( Gilead Sciences):Investing in a high-yielding dividend stock can be a great way to make the most of your money. But to ensure that inflation isn't chipping away at that cash flow over time, you'll also want to invest in a company that raises its dividend payments. With Gilead Sciences, investors are getting the best of both worlds -- a high yield of around 4% that has also been growing over the years.Five years ago, Gilead was paying its investors a quarterly dividend of $0.47. Today, those payments are up to $0.71, rising by 51% during that time and averaging a compound annual growth rate of 8.6%. And that already-juicy dividend can get even more mouth-watering as the company's payout ratio sits below 50%.In Gilead's latest quarterly update, sales rose 13% year over year to $7.4 billion. The company also reported net income of $2.6 billion, which equated to a per-share (diluted) profit of $2.05. And in the nine months leading up to that date, the earnings per share (EPS) topped $4.63. That's easily enough to cover the current dividend, which on an annual basis would total $2.84. And it leaves room for some generous increases as well.Now may be an optimal time to buy Gilead stock. The company typically reports its fourth-quarter earnings in early February. Gilead could announce another dividend hike then as well. Since 2015 when the company began making dividend payments, Gilead has consistently raised its payouts each subsequent year (and normally in February).With solid financials and the company likely to continue receiving a boost from its COVID-19 treatment, Veklury, it's probable that this dividend could get even juicier than it already is today.Prosper Junior Bakiny(Pfizer):When it comes to dividend stocks, high yields are great, but the ability to sustain dividend increases is even better. That's what pharma giant Pfizer provides. The company's current yield of 2.75% is well above the S&P 500's average of 1.27%. But just as important is Pfizer's very conservative cash payout ratio of 29.64%. For context, a payout ratio below the 60% range is generally considered good.This implies that Pfizer has considerable room to sustain dividend increases in large part thanks to the cash it has been generating over the past year. Pfizer's free cash flow soared by 126.1% to $29.2 billion in the trailing twelve-month period. We can attribute that primarily to Pfizer's COVID-19 vaccine, Comirnaty. This vaccine has become ablockbuster product-- and then some -- in its first year on the market.Pfizer said it would generate $36 billion from Comirnaty in the fiscal year 2021. Given recent developments surrounding the pandemic, 2022 should be another excellent year for the vaccine. Management thinks sales of Comirnaty could come in at $29 billion this year. Pfizer's coronavirus-related business alone, which includes Comirnaty and Paxlovid, a COVID-19 therapy that recently earned authorization, will generate more sales than dozens of large corporations will this year.But Pfizer has other tools at its disposal. The company's anticoagulant Eliquis, cancer medicine Xtandi, as well as its biosimilar business, are meaningfully contributing to its overall performance. Even immunosuppressant Xeljanz could return to growth this yeardespite the regulatory headwinds it encountered last year.Lastly, Pfizer's pipeline includes 29 ongoing phase 3 clinical trials. Expect new products and label expansions to strengthen an already solid lineup.And all of this at a reasonable price, too. Pfizer is trading at just 9.1 times forward earnings compared to an average price-to-earnings ratio of 13.3 for the pharma industry.In short, Pfizer provides a little bit of everything most investors look for: high growth, reasonable value, and stable income in the form of dividends. Too juicy to pass up, indeed.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9005759121,"gmtCreate":1642422871750,"gmtModify":1676533709428,"author":{"id":"4087949413245130","authorId":"4087949413245130","name":"HoSeyLiao48","avatar":"https://static.tigerbbs.com/8a9a7795aa16cbb122ca86630c428a3a","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"4087949413245130","idStr":"4087949413245130"},"htmlText":"[Allin]&nbsp;[USD]&nbsp;[Call]&nbsp;[Like]&nbsp;","listText":"[Allin]&nbsp;[USD]&nbsp;[Call]&nbsp;[Like]&nbsp;","text":"[Allin] [USD] [Call] [Like]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9005759121","repostId":1103076176,"repostType":2,"repost":{"id":"1103076176","pubTimestamp":1642404988,"share":"https://ttm.financial/m/news/1103076176?lang=&edition=fundamental","pubTime":"2022-01-17 15:36","market":"us","language":"en","title":"3 Pharma Stocks With Especially Juicy Dividends","url":"https://stock-news.laohu8.com/highlight/detail?id=1103076176","media":"Motley Fool","summary":"Key PointsAbbVie is a Dividend Aristocrat that also performed quite well over the past year.Gilead S","content":"<html><head></head><body><p>Key Points</p><ul><li>AbbVie is a Dividend Aristocrat that also performed quite well over the past year.</li><li>Gilead Sciences has increased its dividend 51% over the last five years and should keep the streak going in 2022.</li><li>Pfizer is a cash cow with a strong and stable dividend.</li></ul><p>Big pharmaceutical companies usually make big bucks. And many of them return a portion of their profits to investors in the form of dividends.</p><p>We asked three Motley Fool contributors to pick the pharma stocks that they think have especially juicy dividends. Here&#39;s why they chose <a href=\"https://laohu8.com/S/ABBV\"><b>AbbVie</b></a>, <a href=\"https://laohu8.com/S/GILD\"><b>Gilead Sciences</b></a>, and <a href=\"https://laohu8.com/S/PFE\"><b>Pfizer</b></a>.</p><p><b>Keith Speights(</b><a href=\"https://laohu8.com/S/ABBV\"><b>AbbVie</b></a><b>):</b>There&#39;s so much to like about AbbVie&#39;s dividend that it&#39;s hard to know where to begin. But I&#39;ll start with its attractive yield of 4.2%. What&#39;s even better, though, is that AbbVie is a Dividend Aristocrat-- an elite group of <b>S&amp;P 500</b>members that have increased their dividends for at least 25 consecutive years.</p><p>Unlike some dividend stocks, AbbVie has also delivered strong growth lately. Its shares soared 26% last year. With dividends included, the drugmaker&#39;s total return easily beat the S&amp;P 500&#39;s performance.</p><p>There are a couple of concerns for AbbVie, though. The U.S. Food and Drug Administration (FDA) recentlyplaced additional warnings on the company&#39;s JAK inhibitor Rinvoq. This could limit the sales of the drug to some extent. Also, AbbVie&#39;s top-selling drug Humira faces biosimilar rivals in the U.S. beginning in 2023. Sales are expected to decline significantly.</p><p>However, AbbVie&#39;s dividend shouldn&#39;t be threatened at all. The company could also continue generating solid growth in the second half of this decade after the initial impact of Humira losing exclusivity. AbbVie has several other growth drivers, including autoimmune disease drug Skyrizi and blood cancer drug Venclexta.</p><p><b>David Jagielski</b> <b>(</b> <a href=\"https://laohu8.com/S/GILD\"><b>Gilead Sciences</b></a><b>):</b>Investing in a high-yielding dividend stock can be a great way to make the most of your money. But to ensure that inflation isn&#39;t chipping away at that cash flow over time, you&#39;ll also want to invest in a company that raises its dividend payments. With Gilead Sciences, investors are getting the best of both worlds -- a high yield of around 4% that has also been growing over the years.</p><p>Five years ago, Gilead was paying its investors a quarterly dividend of $0.47. Today, those payments are up to $0.71, rising by 51% during that time and averaging a compound annual growth rate of 8.6%. And that already-juicy dividend can get even more mouth-watering as the company&#39;s payout ratio sits below 50%.</p><p>In Gilead&#39;s latest quarterly update, sales rose 13% year over year to $7.4 billion. The company also reported net income of $2.6 billion, which equated to a per-share (diluted) profit of $2.05. And in the nine months leading up to that date, the earnings per share (EPS) topped $4.63. That&#39;s easily enough to cover the current dividend, which on an annual basis would total $2.84. And it leaves room for some generous increases as well.</p><p>Now may be an optimal time to buy Gilead stock. The company typically reports its fourth-quarter earnings in early February. Gilead could announce another dividend hike then as well. Since 2015 when the company began making dividend payments, Gilead has consistently raised its payouts each subsequent year (and normally in February).</p><p>With solid financials and the company likely to continue receiving a boost from its COVID-19 treatment, Veklury, it&#39;s probable that this dividend could get even juicier than it already is today.</p><p><b>Prosper Junior Bakiny(</b><a href=\"https://laohu8.com/S/PFE\"><b>Pfizer</b></a><b>):</b>When it comes to dividend stocks, high yields are great, but the ability to sustain dividend increases is even better. That&#39;s what pharma giant Pfizer provides. The company&#39;s current yield of 2.75% is well above the S&amp;P 500&#39;s average of 1.27%. But just as important is Pfizer&#39;s very conservative cash payout ratio of 29.64%. For context, a payout ratio below the 60% range is generally considered good.</p><p>This implies that Pfizer has considerable room to sustain dividend increases in large part thanks to the cash it has been generating over the past year. Pfizer&#39;s free cash flow soared by 126.1% to $29.2 billion in the trailing twelve-month period. We can attribute that primarily to Pfizer&#39;s COVID-19 vaccine, Comirnaty. This vaccine has become ablockbuster product-- and then some -- in its first year on the market.</p><p>Pfizer said it would generate $36 billion from Comirnaty in the fiscal year 2021. Given recent developments surrounding the pandemic, 2022 should be another excellent year for the vaccine. Management thinks sales of Comirnaty could come in at $29 billion this year. Pfizer&#39;s coronavirus-related business alone, which includes Comirnaty and Paxlovid, a COVID-19 therapy that recently earned authorization, will generate more sales than dozens of large corporations will this year.</p><p>But Pfizer has other tools at its disposal. The company&#39;s anticoagulant Eliquis, cancer medicine Xtandi, as well as its biosimilar business, are meaningfully contributing to its overall performance. Even immunosuppressant Xeljanz could return to growth this yeardespite the regulatory headwinds it encountered last year.</p><p>Lastly, Pfizer&#39;s pipeline includes 29 ongoing phase 3 clinical trials. Expect new products and label expansions to strengthen an already solid lineup.</p><p>And all of this at a reasonable price, too. Pfizer is trading at just 9.1 times forward earnings compared to an average price-to-earnings ratio of 13.3 for the pharma industry.</p><p>In short, Pfizer provides a little bit of everything most investors look for: high growth, reasonable value, and stable income in the form of dividends. Too juicy to pass up, indeed.</p><p></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Pharma Stocks With Especially Juicy Dividends</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Pharma Stocks With Especially Juicy Dividends\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-17 15:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/16/3-pharma-stocks-with-especially-juicy-dividends/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Key PointsAbbVie is a Dividend Aristocrat that also performed quite well over the past year.Gilead Sciences has increased its dividend 51% over the last five years and should keep the streak going in ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/16/3-pharma-stocks-with-especially-juicy-dividends/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GILD":"吉利德科学","ABBV":"艾伯维公司","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2022/01/16/3-pharma-stocks-with-especially-juicy-dividends/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1103076176","content_text":"Key PointsAbbVie is a Dividend Aristocrat that also performed quite well over the past year.Gilead Sciences has increased its dividend 51% over the last five years and should keep the streak going in 2022.Pfizer is a cash cow with a strong and stable dividend.Big pharmaceutical companies usually make big bucks. And many of them return a portion of their profits to investors in the form of dividends.We asked three Motley Fool contributors to pick the pharma stocks that they think have especially juicy dividends. Here's why they chose AbbVie, Gilead Sciences, and Pfizer.Keith Speights(AbbVie):There's so much to like about AbbVie's dividend that it's hard to know where to begin. But I'll start with its attractive yield of 4.2%. What's even better, though, is that AbbVie is a Dividend Aristocrat-- an elite group of S&P 500members that have increased their dividends for at least 25 consecutive years.Unlike some dividend stocks, AbbVie has also delivered strong growth lately. Its shares soared 26% last year. With dividends included, the drugmaker's total return easily beat the S&P 500's performance.There are a couple of concerns for AbbVie, though. The U.S. Food and Drug Administration (FDA) recentlyplaced additional warnings on the company's JAK inhibitor Rinvoq. This could limit the sales of the drug to some extent. Also, AbbVie's top-selling drug Humira faces biosimilar rivals in the U.S. beginning in 2023. Sales are expected to decline significantly.However, AbbVie's dividend shouldn't be threatened at all. The company could also continue generating solid growth in the second half of this decade after the initial impact of Humira losing exclusivity. AbbVie has several other growth drivers, including autoimmune disease drug Skyrizi and blood cancer drug Venclexta.David Jagielski ( Gilead Sciences):Investing in a high-yielding dividend stock can be a great way to make the most of your money. But to ensure that inflation isn't chipping away at that cash flow over time, you'll also want to invest in a company that raises its dividend payments. With Gilead Sciences, investors are getting the best of both worlds -- a high yield of around 4% that has also been growing over the years.Five years ago, Gilead was paying its investors a quarterly dividend of $0.47. Today, those payments are up to $0.71, rising by 51% during that time and averaging a compound annual growth rate of 8.6%. And that already-juicy dividend can get even more mouth-watering as the company's payout ratio sits below 50%.In Gilead's latest quarterly update, sales rose 13% year over year to $7.4 billion. The company also reported net income of $2.6 billion, which equated to a per-share (diluted) profit of $2.05. And in the nine months leading up to that date, the earnings per share (EPS) topped $4.63. That's easily enough to cover the current dividend, which on an annual basis would total $2.84. And it leaves room for some generous increases as well.Now may be an optimal time to buy Gilead stock. The company typically reports its fourth-quarter earnings in early February. Gilead could announce another dividend hike then as well. Since 2015 when the company began making dividend payments, Gilead has consistently raised its payouts each subsequent year (and normally in February).With solid financials and the company likely to continue receiving a boost from its COVID-19 treatment, Veklury, it's probable that this dividend could get even juicier than it already is today.Prosper Junior Bakiny(Pfizer):When it comes to dividend stocks, high yields are great, but the ability to sustain dividend increases is even better. That's what pharma giant Pfizer provides. The company's current yield of 2.75% is well above the S&P 500's average of 1.27%. But just as important is Pfizer's very conservative cash payout ratio of 29.64%. For context, a payout ratio below the 60% range is generally considered good.This implies that Pfizer has considerable room to sustain dividend increases in large part thanks to the cash it has been generating over the past year. Pfizer's free cash flow soared by 126.1% to $29.2 billion in the trailing twelve-month period. We can attribute that primarily to Pfizer's COVID-19 vaccine, Comirnaty. This vaccine has become ablockbuster product-- and then some -- in its first year on the market.Pfizer said it would generate $36 billion from Comirnaty in the fiscal year 2021. Given recent developments surrounding the pandemic, 2022 should be another excellent year for the vaccine. Management thinks sales of Comirnaty could come in at $29 billion this year. Pfizer's coronavirus-related business alone, which includes Comirnaty and Paxlovid, a COVID-19 therapy that recently earned authorization, will generate more sales than dozens of large corporations will this year.But Pfizer has other tools at its disposal. The company's anticoagulant Eliquis, cancer medicine Xtandi, as well as its biosimilar business, are meaningfully contributing to its overall performance. Even immunosuppressant Xeljanz could return to growth this yeardespite the regulatory headwinds it encountered last year.Lastly, Pfizer's pipeline includes 29 ongoing phase 3 clinical trials. Expect new products and label expansions to strengthen an already solid lineup.And all of this at a reasonable price, too. Pfizer is trading at just 9.1 times forward earnings compared to an average price-to-earnings ratio of 13.3 for the pharma industry.In short, Pfizer provides a little bit of everything most investors look for: high growth, reasonable value, and stable income in the form of dividends. Too juicy to pass up, indeed.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9005728522,"gmtCreate":1642420045291,"gmtModify":1676533709270,"author":{"id":"3573471374708502","authorId":"3573471374708502","name":"RetiredPig83","avatar":"https://static.tigerbbs.com/5595baccc3331b6777d7c9f0c077ecc1","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":3,"crmLevelSwitch":0,"authorIdStr":"3573471374708502","idStr":"3573471374708502"},"htmlText":"Like 👍&nbsp;","listText":"Like 👍&nbsp;","text":"Like 👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9005728522","repostId":1103076176,"repostType":4,"repost":{"id":"1103076176","pubTimestamp":1642404988,"share":"https://ttm.financial/m/news/1103076176?lang=&edition=fundamental","pubTime":"2022-01-17 15:36","market":"us","language":"en","title":"3 Pharma Stocks With Especially Juicy Dividends","url":"https://stock-news.laohu8.com/highlight/detail?id=1103076176","media":"Motley Fool","summary":"Key PointsAbbVie is a Dividend Aristocrat that also performed quite well over the past year.Gilead S","content":"<html><head></head><body><p>Key Points</p><ul><li>AbbVie is a Dividend Aristocrat that also performed quite well over the past year.</li><li>Gilead Sciences has increased its dividend 51% over the last five years and should keep the streak going in 2022.</li><li>Pfizer is a cash cow with a strong and stable dividend.</li></ul><p>Big pharmaceutical companies usually make big bucks. And many of them return a portion of their profits to investors in the form of dividends.</p><p>We asked three Motley Fool contributors to pick the pharma stocks that they think have especially juicy dividends. Here&#39;s why they chose <a href=\"https://laohu8.com/S/ABBV\"><b>AbbVie</b></a>, <a href=\"https://laohu8.com/S/GILD\"><b>Gilead Sciences</b></a>, and <a href=\"https://laohu8.com/S/PFE\"><b>Pfizer</b></a>.</p><p><b>Keith Speights(</b><a href=\"https://laohu8.com/S/ABBV\"><b>AbbVie</b></a><b>):</b>There&#39;s so much to like about AbbVie&#39;s dividend that it&#39;s hard to know where to begin. But I&#39;ll start with its attractive yield of 4.2%. What&#39;s even better, though, is that AbbVie is a Dividend Aristocrat-- an elite group of <b>S&amp;P 500</b>members that have increased their dividends for at least 25 consecutive years.</p><p>Unlike some dividend stocks, AbbVie has also delivered strong growth lately. Its shares soared 26% last year. With dividends included, the drugmaker&#39;s total return easily beat the S&amp;P 500&#39;s performance.</p><p>There are a couple of concerns for AbbVie, though. The U.S. Food and Drug Administration (FDA) recentlyplaced additional warnings on the company&#39;s JAK inhibitor Rinvoq. This could limit the sales of the drug to some extent. Also, AbbVie&#39;s top-selling drug Humira faces biosimilar rivals in the U.S. beginning in 2023. Sales are expected to decline significantly.</p><p>However, AbbVie&#39;s dividend shouldn&#39;t be threatened at all. The company could also continue generating solid growth in the second half of this decade after the initial impact of Humira losing exclusivity. AbbVie has several other growth drivers, including autoimmune disease drug Skyrizi and blood cancer drug Venclexta.</p><p><b>David Jagielski</b> <b>(</b> <a href=\"https://laohu8.com/S/GILD\"><b>Gilead Sciences</b></a><b>):</b>Investing in a high-yielding dividend stock can be a great way to make the most of your money. But to ensure that inflation isn&#39;t chipping away at that cash flow over time, you&#39;ll also want to invest in a company that raises its dividend payments. With Gilead Sciences, investors are getting the best of both worlds -- a high yield of around 4% that has also been growing over the years.</p><p>Five years ago, Gilead was paying its investors a quarterly dividend of $0.47. Today, those payments are up to $0.71, rising by 51% during that time and averaging a compound annual growth rate of 8.6%. And that already-juicy dividend can get even more mouth-watering as the company&#39;s payout ratio sits below 50%.</p><p>In Gilead&#39;s latest quarterly update, sales rose 13% year over year to $7.4 billion. The company also reported net income of $2.6 billion, which equated to a per-share (diluted) profit of $2.05. And in the nine months leading up to that date, the earnings per share (EPS) topped $4.63. That&#39;s easily enough to cover the current dividend, which on an annual basis would total $2.84. And it leaves room for some generous increases as well.</p><p>Now may be an optimal time to buy Gilead stock. The company typically reports its fourth-quarter earnings in early February. Gilead could announce another dividend hike then as well. Since 2015 when the company began making dividend payments, Gilead has consistently raised its payouts each subsequent year (and normally in February).</p><p>With solid financials and the company likely to continue receiving a boost from its COVID-19 treatment, Veklury, it&#39;s probable that this dividend could get even juicier than it already is today.</p><p><b>Prosper Junior Bakiny(</b><a href=\"https://laohu8.com/S/PFE\"><b>Pfizer</b></a><b>):</b>When it comes to dividend stocks, high yields are great, but the ability to sustain dividend increases is even better. That&#39;s what pharma giant Pfizer provides. The company&#39;s current yield of 2.75% is well above the S&amp;P 500&#39;s average of 1.27%. But just as important is Pfizer&#39;s very conservative cash payout ratio of 29.64%. For context, a payout ratio below the 60% range is generally considered good.</p><p>This implies that Pfizer has considerable room to sustain dividend increases in large part thanks to the cash it has been generating over the past year. Pfizer&#39;s free cash flow soared by 126.1% to $29.2 billion in the trailing twelve-month period. We can attribute that primarily to Pfizer&#39;s COVID-19 vaccine, Comirnaty. This vaccine has become ablockbuster product-- and then some -- in its first year on the market.</p><p>Pfizer said it would generate $36 billion from Comirnaty in the fiscal year 2021. Given recent developments surrounding the pandemic, 2022 should be another excellent year for the vaccine. Management thinks sales of Comirnaty could come in at $29 billion this year. Pfizer&#39;s coronavirus-related business alone, which includes Comirnaty and Paxlovid, a COVID-19 therapy that recently earned authorization, will generate more sales than dozens of large corporations will this year.</p><p>But Pfizer has other tools at its disposal. The company&#39;s anticoagulant Eliquis, cancer medicine Xtandi, as well as its biosimilar business, are meaningfully contributing to its overall performance. Even immunosuppressant Xeljanz could return to growth this yeardespite the regulatory headwinds it encountered last year.</p><p>Lastly, Pfizer&#39;s pipeline includes 29 ongoing phase 3 clinical trials. Expect new products and label expansions to strengthen an already solid lineup.</p><p>And all of this at a reasonable price, too. Pfizer is trading at just 9.1 times forward earnings compared to an average price-to-earnings ratio of 13.3 for the pharma industry.</p><p>In short, Pfizer provides a little bit of everything most investors look for: high growth, reasonable value, and stable income in the form of dividends. Too juicy to pass up, indeed.</p><p></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Pharma Stocks With Especially Juicy Dividends</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Pharma Stocks With Especially Juicy Dividends\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-17 15:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/16/3-pharma-stocks-with-especially-juicy-dividends/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Key PointsAbbVie is a Dividend Aristocrat that also performed quite well over the past year.Gilead Sciences has increased its dividend 51% over the last five years and should keep the streak going in ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/16/3-pharma-stocks-with-especially-juicy-dividends/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GILD":"吉利德科学","ABBV":"艾伯维公司","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2022/01/16/3-pharma-stocks-with-especially-juicy-dividends/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1103076176","content_text":"Key PointsAbbVie is a Dividend Aristocrat that also performed quite well over the past year.Gilead Sciences has increased its dividend 51% over the last five years and should keep the streak going in 2022.Pfizer is a cash cow with a strong and stable dividend.Big pharmaceutical companies usually make big bucks. And many of them return a portion of their profits to investors in the form of dividends.We asked three Motley Fool contributors to pick the pharma stocks that they think have especially juicy dividends. Here's why they chose AbbVie, Gilead Sciences, and Pfizer.Keith Speights(AbbVie):There's so much to like about AbbVie's dividend that it's hard to know where to begin. But I'll start with its attractive yield of 4.2%. What's even better, though, is that AbbVie is a Dividend Aristocrat-- an elite group of S&P 500members that have increased their dividends for at least 25 consecutive years.Unlike some dividend stocks, AbbVie has also delivered strong growth lately. Its shares soared 26% last year. With dividends included, the drugmaker's total return easily beat the S&P 500's performance.There are a couple of concerns for AbbVie, though. The U.S. Food and Drug Administration (FDA) recentlyplaced additional warnings on the company's JAK inhibitor Rinvoq. This could limit the sales of the drug to some extent. Also, AbbVie's top-selling drug Humira faces biosimilar rivals in the U.S. beginning in 2023. Sales are expected to decline significantly.However, AbbVie's dividend shouldn't be threatened at all. The company could also continue generating solid growth in the second half of this decade after the initial impact of Humira losing exclusivity. AbbVie has several other growth drivers, including autoimmune disease drug Skyrizi and blood cancer drug Venclexta.David Jagielski ( Gilead Sciences):Investing in a high-yielding dividend stock can be a great way to make the most of your money. But to ensure that inflation isn't chipping away at that cash flow over time, you'll also want to invest in a company that raises its dividend payments. With Gilead Sciences, investors are getting the best of both worlds -- a high yield of around 4% that has also been growing over the years.Five years ago, Gilead was paying its investors a quarterly dividend of $0.47. Today, those payments are up to $0.71, rising by 51% during that time and averaging a compound annual growth rate of 8.6%. And that already-juicy dividend can get even more mouth-watering as the company's payout ratio sits below 50%.In Gilead's latest quarterly update, sales rose 13% year over year to $7.4 billion. The company also reported net income of $2.6 billion, which equated to a per-share (diluted) profit of $2.05. And in the nine months leading up to that date, the earnings per share (EPS) topped $4.63. That's easily enough to cover the current dividend, which on an annual basis would total $2.84. And it leaves room for some generous increases as well.Now may be an optimal time to buy Gilead stock. The company typically reports its fourth-quarter earnings in early February. Gilead could announce another dividend hike then as well. Since 2015 when the company began making dividend payments, Gilead has consistently raised its payouts each subsequent year (and normally in February).With solid financials and the company likely to continue receiving a boost from its COVID-19 treatment, Veklury, it's probable that this dividend could get even juicier than it already is today.Prosper Junior Bakiny(Pfizer):When it comes to dividend stocks, high yields are great, but the ability to sustain dividend increases is even better. That's what pharma giant Pfizer provides. The company's current yield of 2.75% is well above the S&P 500's average of 1.27%. But just as important is Pfizer's very conservative cash payout ratio of 29.64%. For context, a payout ratio below the 60% range is generally considered good.This implies that Pfizer has considerable room to sustain dividend increases in large part thanks to the cash it has been generating over the past year. Pfizer's free cash flow soared by 126.1% to $29.2 billion in the trailing twelve-month period. We can attribute that primarily to Pfizer's COVID-19 vaccine, Comirnaty. This vaccine has become ablockbuster product-- and then some -- in its first year on the market.Pfizer said it would generate $36 billion from Comirnaty in the fiscal year 2021. Given recent developments surrounding the pandemic, 2022 should be another excellent year for the vaccine. Management thinks sales of Comirnaty could come in at $29 billion this year. Pfizer's coronavirus-related business alone, which includes Comirnaty and Paxlovid, a COVID-19 therapy that recently earned authorization, will generate more sales than dozens of large corporations will this year.But Pfizer has other tools at its disposal. The company's anticoagulant Eliquis, cancer medicine Xtandi, as well as its biosimilar business, are meaningfully contributing to its overall performance. Even immunosuppressant Xeljanz could return to growth this yeardespite the regulatory headwinds it encountered last year.Lastly, Pfizer's pipeline includes 29 ongoing phase 3 clinical trials. Expect new products and label expansions to strengthen an already solid lineup.And all of this at a reasonable price, too. Pfizer is trading at just 9.1 times forward earnings compared to an average price-to-earnings ratio of 13.3 for the pharma industry.In short, Pfizer provides a little bit of everything most investors look for: high growth, reasonable value, and stable income in the form of dividends. Too juicy to pass up, indeed.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9005767163,"gmtCreate":1642418062316,"gmtModify":1676533709060,"author":{"id":"4094435594173410","authorId":"4094435594173410","name":"aden53","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"4094435594173410","idStr":"4094435594173410"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9005767163","repostId":1103076176,"repostType":2,"repost":{"id":"1103076176","pubTimestamp":1642404988,"share":"https://ttm.financial/m/news/1103076176?lang=&edition=fundamental","pubTime":"2022-01-17 15:36","market":"us","language":"en","title":"3 Pharma Stocks With Especially Juicy Dividends","url":"https://stock-news.laohu8.com/highlight/detail?id=1103076176","media":"Motley Fool","summary":"Key PointsAbbVie is a Dividend Aristocrat that also performed quite well over the past year.Gilead S","content":"<html><head></head><body><p>Key Points</p><ul><li>AbbVie is a Dividend Aristocrat that also performed quite well over the past year.</li><li>Gilead Sciences has increased its dividend 51% over the last five years and should keep the streak going in 2022.</li><li>Pfizer is a cash cow with a strong and stable dividend.</li></ul><p>Big pharmaceutical companies usually make big bucks. And many of them return a portion of their profits to investors in the form of dividends.</p><p>We asked three Motley Fool contributors to pick the pharma stocks that they think have especially juicy dividends. Here&#39;s why they chose <a href=\"https://laohu8.com/S/ABBV\"><b>AbbVie</b></a>, <a href=\"https://laohu8.com/S/GILD\"><b>Gilead Sciences</b></a>, and <a href=\"https://laohu8.com/S/PFE\"><b>Pfizer</b></a>.</p><p><b>Keith Speights(</b><a href=\"https://laohu8.com/S/ABBV\"><b>AbbVie</b></a><b>):</b>There&#39;s so much to like about AbbVie&#39;s dividend that it&#39;s hard to know where to begin. But I&#39;ll start with its attractive yield of 4.2%. What&#39;s even better, though, is that AbbVie is a Dividend Aristocrat-- an elite group of <b>S&amp;P 500</b>members that have increased their dividends for at least 25 consecutive years.</p><p>Unlike some dividend stocks, AbbVie has also delivered strong growth lately. Its shares soared 26% last year. With dividends included, the drugmaker&#39;s total return easily beat the S&amp;P 500&#39;s performance.</p><p>There are a couple of concerns for AbbVie, though. The U.S. Food and Drug Administration (FDA) recentlyplaced additional warnings on the company&#39;s JAK inhibitor Rinvoq. This could limit the sales of the drug to some extent. Also, AbbVie&#39;s top-selling drug Humira faces biosimilar rivals in the U.S. beginning in 2023. Sales are expected to decline significantly.</p><p>However, AbbVie&#39;s dividend shouldn&#39;t be threatened at all. The company could also continue generating solid growth in the second half of this decade after the initial impact of Humira losing exclusivity. AbbVie has several other growth drivers, including autoimmune disease drug Skyrizi and blood cancer drug Venclexta.</p><p><b>David Jagielski</b> <b>(</b> <a href=\"https://laohu8.com/S/GILD\"><b>Gilead Sciences</b></a><b>):</b>Investing in a high-yielding dividend stock can be a great way to make the most of your money. But to ensure that inflation isn&#39;t chipping away at that cash flow over time, you&#39;ll also want to invest in a company that raises its dividend payments. With Gilead Sciences, investors are getting the best of both worlds -- a high yield of around 4% that has also been growing over the years.</p><p>Five years ago, Gilead was paying its investors a quarterly dividend of $0.47. Today, those payments are up to $0.71, rising by 51% during that time and averaging a compound annual growth rate of 8.6%. And that already-juicy dividend can get even more mouth-watering as the company&#39;s payout ratio sits below 50%.</p><p>In Gilead&#39;s latest quarterly update, sales rose 13% year over year to $7.4 billion. The company also reported net income of $2.6 billion, which equated to a per-share (diluted) profit of $2.05. And in the nine months leading up to that date, the earnings per share (EPS) topped $4.63. That&#39;s easily enough to cover the current dividend, which on an annual basis would total $2.84. And it leaves room for some generous increases as well.</p><p>Now may be an optimal time to buy Gilead stock. The company typically reports its fourth-quarter earnings in early February. Gilead could announce another dividend hike then as well. Since 2015 when the company began making dividend payments, Gilead has consistently raised its payouts each subsequent year (and normally in February).</p><p>With solid financials and the company likely to continue receiving a boost from its COVID-19 treatment, Veklury, it&#39;s probable that this dividend could get even juicier than it already is today.</p><p><b>Prosper Junior Bakiny(</b><a href=\"https://laohu8.com/S/PFE\"><b>Pfizer</b></a><b>):</b>When it comes to dividend stocks, high yields are great, but the ability to sustain dividend increases is even better. That&#39;s what pharma giant Pfizer provides. The company&#39;s current yield of 2.75% is well above the S&amp;P 500&#39;s average of 1.27%. But just as important is Pfizer&#39;s very conservative cash payout ratio of 29.64%. For context, a payout ratio below the 60% range is generally considered good.</p><p>This implies that Pfizer has considerable room to sustain dividend increases in large part thanks to the cash it has been generating over the past year. Pfizer&#39;s free cash flow soared by 126.1% to $29.2 billion in the trailing twelve-month period. We can attribute that primarily to Pfizer&#39;s COVID-19 vaccine, Comirnaty. This vaccine has become ablockbuster product-- and then some -- in its first year on the market.</p><p>Pfizer said it would generate $36 billion from Comirnaty in the fiscal year 2021. Given recent developments surrounding the pandemic, 2022 should be another excellent year for the vaccine. Management thinks sales of Comirnaty could come in at $29 billion this year. Pfizer&#39;s coronavirus-related business alone, which includes Comirnaty and Paxlovid, a COVID-19 therapy that recently earned authorization, will generate more sales than dozens of large corporations will this year.</p><p>But Pfizer has other tools at its disposal. The company&#39;s anticoagulant Eliquis, cancer medicine Xtandi, as well as its biosimilar business, are meaningfully contributing to its overall performance. Even immunosuppressant Xeljanz could return to growth this yeardespite the regulatory headwinds it encountered last year.</p><p>Lastly, Pfizer&#39;s pipeline includes 29 ongoing phase 3 clinical trials. Expect new products and label expansions to strengthen an already solid lineup.</p><p>And all of this at a reasonable price, too. Pfizer is trading at just 9.1 times forward earnings compared to an average price-to-earnings ratio of 13.3 for the pharma industry.</p><p>In short, Pfizer provides a little bit of everything most investors look for: high growth, reasonable value, and stable income in the form of dividends. Too juicy to pass up, indeed.</p><p></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Pharma Stocks With Especially Juicy Dividends</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Pharma Stocks With Especially Juicy Dividends\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-17 15:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/16/3-pharma-stocks-with-especially-juicy-dividends/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Key PointsAbbVie is a Dividend Aristocrat that also performed quite well over the past year.Gilead Sciences has increased its dividend 51% over the last five years and should keep the streak going in ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/16/3-pharma-stocks-with-especially-juicy-dividends/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GILD":"吉利德科学","ABBV":"艾伯维公司","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2022/01/16/3-pharma-stocks-with-especially-juicy-dividends/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1103076176","content_text":"Key PointsAbbVie is a Dividend Aristocrat that also performed quite well over the past year.Gilead Sciences has increased its dividend 51% over the last five years and should keep the streak going in 2022.Pfizer is a cash cow with a strong and stable dividend.Big pharmaceutical companies usually make big bucks. And many of them return a portion of their profits to investors in the form of dividends.We asked three Motley Fool contributors to pick the pharma stocks that they think have especially juicy dividends. Here's why they chose AbbVie, Gilead Sciences, and Pfizer.Keith Speights(AbbVie):There's so much to like about AbbVie's dividend that it's hard to know where to begin. But I'll start with its attractive yield of 4.2%. What's even better, though, is that AbbVie is a Dividend Aristocrat-- an elite group of S&P 500members that have increased their dividends for at least 25 consecutive years.Unlike some dividend stocks, AbbVie has also delivered strong growth lately. Its shares soared 26% last year. With dividends included, the drugmaker's total return easily beat the S&P 500's performance.There are a couple of concerns for AbbVie, though. The U.S. Food and Drug Administration (FDA) recentlyplaced additional warnings on the company's JAK inhibitor Rinvoq. This could limit the sales of the drug to some extent. Also, AbbVie's top-selling drug Humira faces biosimilar rivals in the U.S. beginning in 2023. Sales are expected to decline significantly.However, AbbVie's dividend shouldn't be threatened at all. The company could also continue generating solid growth in the second half of this decade after the initial impact of Humira losing exclusivity. AbbVie has several other growth drivers, including autoimmune disease drug Skyrizi and blood cancer drug Venclexta.David Jagielski ( Gilead Sciences):Investing in a high-yielding dividend stock can be a great way to make the most of your money. But to ensure that inflation isn't chipping away at that cash flow over time, you'll also want to invest in a company that raises its dividend payments. With Gilead Sciences, investors are getting the best of both worlds -- a high yield of around 4% that has also been growing over the years.Five years ago, Gilead was paying its investors a quarterly dividend of $0.47. Today, those payments are up to $0.71, rising by 51% during that time and averaging a compound annual growth rate of 8.6%. And that already-juicy dividend can get even more mouth-watering as the company's payout ratio sits below 50%.In Gilead's latest quarterly update, sales rose 13% year over year to $7.4 billion. The company also reported net income of $2.6 billion, which equated to a per-share (diluted) profit of $2.05. And in the nine months leading up to that date, the earnings per share (EPS) topped $4.63. That's easily enough to cover the current dividend, which on an annual basis would total $2.84. And it leaves room for some generous increases as well.Now may be an optimal time to buy Gilead stock. The company typically reports its fourth-quarter earnings in early February. Gilead could announce another dividend hike then as well. Since 2015 when the company began making dividend payments, Gilead has consistently raised its payouts each subsequent year (and normally in February).With solid financials and the company likely to continue receiving a boost from its COVID-19 treatment, Veklury, it's probable that this dividend could get even juicier than it already is today.Prosper Junior Bakiny(Pfizer):When it comes to dividend stocks, high yields are great, but the ability to sustain dividend increases is even better. That's what pharma giant Pfizer provides. The company's current yield of 2.75% is well above the S&P 500's average of 1.27%. But just as important is Pfizer's very conservative cash payout ratio of 29.64%. For context, a payout ratio below the 60% range is generally considered good.This implies that Pfizer has considerable room to sustain dividend increases in large part thanks to the cash it has been generating over the past year. Pfizer's free cash flow soared by 126.1% to $29.2 billion in the trailing twelve-month period. We can attribute that primarily to Pfizer's COVID-19 vaccine, Comirnaty. This vaccine has become ablockbuster product-- and then some -- in its first year on the market.Pfizer said it would generate $36 billion from Comirnaty in the fiscal year 2021. Given recent developments surrounding the pandemic, 2022 should be another excellent year for the vaccine. Management thinks sales of Comirnaty could come in at $29 billion this year. Pfizer's coronavirus-related business alone, which includes Comirnaty and Paxlovid, a COVID-19 therapy that recently earned authorization, will generate more sales than dozens of large corporations will this year.But Pfizer has other tools at its disposal. The company's anticoagulant Eliquis, cancer medicine Xtandi, as well as its biosimilar business, are meaningfully contributing to its overall performance. Even immunosuppressant Xeljanz could return to growth this yeardespite the regulatory headwinds it encountered last year.Lastly, Pfizer's pipeline includes 29 ongoing phase 3 clinical trials. Expect new products and label expansions to strengthen an already solid lineup.And all of this at a reasonable price, too. Pfizer is trading at just 9.1 times forward earnings compared to an average price-to-earnings ratio of 13.3 for the pharma industry.In short, Pfizer provides a little bit of everything most investors look for: high growth, reasonable value, and stable income in the form of dividends. Too juicy to pass up, indeed.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9005764239,"gmtCreate":1642417588726,"gmtModify":1676533709149,"author":{"id":"4103727627909910","authorId":"4103727627909910","name":"lanangqupu","avatar":"https://static.tigerbbs.com/15422139911b577386175cb0d4753c40","vip":1,"crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"4103727627909910","idStr":"4103727627909910"},"htmlText":"New Opportunity for us..good idea","listText":"New Opportunity for us..good idea","text":"New Opportunity for us..good idea","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9005764239","repostId":1103076176,"repostType":2,"repost":{"id":"1103076176","pubTimestamp":1642404988,"share":"https://ttm.financial/m/news/1103076176?lang=&edition=fundamental","pubTime":"2022-01-17 15:36","market":"us","language":"en","title":"3 Pharma Stocks With Especially Juicy Dividends","url":"https://stock-news.laohu8.com/highlight/detail?id=1103076176","media":"Motley Fool","summary":"Key PointsAbbVie is a Dividend Aristocrat that also performed quite well over the past year.Gilead S","content":"<html><head></head><body><p>Key Points</p><ul><li>AbbVie is a Dividend Aristocrat that also performed quite well over the past year.</li><li>Gilead Sciences has increased its dividend 51% over the last five years and should keep the streak going in 2022.</li><li>Pfizer is a cash cow with a strong and stable dividend.</li></ul><p>Big pharmaceutical companies usually make big bucks. And many of them return a portion of their profits to investors in the form of dividends.</p><p>We asked three Motley Fool contributors to pick the pharma stocks that they think have especially juicy dividends. Here&#39;s why they chose <a href=\"https://laohu8.com/S/ABBV\"><b>AbbVie</b></a>, <a href=\"https://laohu8.com/S/GILD\"><b>Gilead Sciences</b></a>, and <a href=\"https://laohu8.com/S/PFE\"><b>Pfizer</b></a>.</p><p><b>Keith Speights(</b><a href=\"https://laohu8.com/S/ABBV\"><b>AbbVie</b></a><b>):</b>There&#39;s so much to like about AbbVie&#39;s dividend that it&#39;s hard to know where to begin. But I&#39;ll start with its attractive yield of 4.2%. What&#39;s even better, though, is that AbbVie is a Dividend Aristocrat-- an elite group of <b>S&amp;P 500</b>members that have increased their dividends for at least 25 consecutive years.</p><p>Unlike some dividend stocks, AbbVie has also delivered strong growth lately. Its shares soared 26% last year. With dividends included, the drugmaker&#39;s total return easily beat the S&amp;P 500&#39;s performance.</p><p>There are a couple of concerns for AbbVie, though. The U.S. Food and Drug Administration (FDA) recentlyplaced additional warnings on the company&#39;s JAK inhibitor Rinvoq. This could limit the sales of the drug to some extent. Also, AbbVie&#39;s top-selling drug Humira faces biosimilar rivals in the U.S. beginning in 2023. Sales are expected to decline significantly.</p><p>However, AbbVie&#39;s dividend shouldn&#39;t be threatened at all. The company could also continue generating solid growth in the second half of this decade after the initial impact of Humira losing exclusivity. AbbVie has several other growth drivers, including autoimmune disease drug Skyrizi and blood cancer drug Venclexta.</p><p><b>David Jagielski</b> <b>(</b> <a href=\"https://laohu8.com/S/GILD\"><b>Gilead Sciences</b></a><b>):</b>Investing in a high-yielding dividend stock can be a great way to make the most of your money. But to ensure that inflation isn&#39;t chipping away at that cash flow over time, you&#39;ll also want to invest in a company that raises its dividend payments. With Gilead Sciences, investors are getting the best of both worlds -- a high yield of around 4% that has also been growing over the years.</p><p>Five years ago, Gilead was paying its investors a quarterly dividend of $0.47. Today, those payments are up to $0.71, rising by 51% during that time and averaging a compound annual growth rate of 8.6%. And that already-juicy dividend can get even more mouth-watering as the company&#39;s payout ratio sits below 50%.</p><p>In Gilead&#39;s latest quarterly update, sales rose 13% year over year to $7.4 billion. The company also reported net income of $2.6 billion, which equated to a per-share (diluted) profit of $2.05. And in the nine months leading up to that date, the earnings per share (EPS) topped $4.63. That&#39;s easily enough to cover the current dividend, which on an annual basis would total $2.84. And it leaves room for some generous increases as well.</p><p>Now may be an optimal time to buy Gilead stock. The company typically reports its fourth-quarter earnings in early February. Gilead could announce another dividend hike then as well. Since 2015 when the company began making dividend payments, Gilead has consistently raised its payouts each subsequent year (and normally in February).</p><p>With solid financials and the company likely to continue receiving a boost from its COVID-19 treatment, Veklury, it&#39;s probable that this dividend could get even juicier than it already is today.</p><p><b>Prosper Junior Bakiny(</b><a href=\"https://laohu8.com/S/PFE\"><b>Pfizer</b></a><b>):</b>When it comes to dividend stocks, high yields are great, but the ability to sustain dividend increases is even better. That&#39;s what pharma giant Pfizer provides. The company&#39;s current yield of 2.75% is well above the S&amp;P 500&#39;s average of 1.27%. But just as important is Pfizer&#39;s very conservative cash payout ratio of 29.64%. For context, a payout ratio below the 60% range is generally considered good.</p><p>This implies that Pfizer has considerable room to sustain dividend increases in large part thanks to the cash it has been generating over the past year. Pfizer&#39;s free cash flow soared by 126.1% to $29.2 billion in the trailing twelve-month period. We can attribute that primarily to Pfizer&#39;s COVID-19 vaccine, Comirnaty. This vaccine has become ablockbuster product-- and then some -- in its first year on the market.</p><p>Pfizer said it would generate $36 billion from Comirnaty in the fiscal year 2021. Given recent developments surrounding the pandemic, 2022 should be another excellent year for the vaccine. Management thinks sales of Comirnaty could come in at $29 billion this year. Pfizer&#39;s coronavirus-related business alone, which includes Comirnaty and Paxlovid, a COVID-19 therapy that recently earned authorization, will generate more sales than dozens of large corporations will this year.</p><p>But Pfizer has other tools at its disposal. The company&#39;s anticoagulant Eliquis, cancer medicine Xtandi, as well as its biosimilar business, are meaningfully contributing to its overall performance. Even immunosuppressant Xeljanz could return to growth this yeardespite the regulatory headwinds it encountered last year.</p><p>Lastly, Pfizer&#39;s pipeline includes 29 ongoing phase 3 clinical trials. Expect new products and label expansions to strengthen an already solid lineup.</p><p>And all of this at a reasonable price, too. Pfizer is trading at just 9.1 times forward earnings compared to an average price-to-earnings ratio of 13.3 for the pharma industry.</p><p>In short, Pfizer provides a little bit of everything most investors look for: high growth, reasonable value, and stable income in the form of dividends. Too juicy to pass up, indeed.</p><p></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Pharma Stocks With Especially Juicy Dividends</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Pharma Stocks With Especially Juicy Dividends\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-17 15:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/16/3-pharma-stocks-with-especially-juicy-dividends/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Key PointsAbbVie is a Dividend Aristocrat that also performed quite well over the past year.Gilead Sciences has increased its dividend 51% over the last five years and should keep the streak going in ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/16/3-pharma-stocks-with-especially-juicy-dividends/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GILD":"吉利德科学","ABBV":"艾伯维公司","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2022/01/16/3-pharma-stocks-with-especially-juicy-dividends/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1103076176","content_text":"Key PointsAbbVie is a Dividend Aristocrat that also performed quite well over the past year.Gilead Sciences has increased its dividend 51% over the last five years and should keep the streak going in 2022.Pfizer is a cash cow with a strong and stable dividend.Big pharmaceutical companies usually make big bucks. And many of them return a portion of their profits to investors in the form of dividends.We asked three Motley Fool contributors to pick the pharma stocks that they think have especially juicy dividends. Here's why they chose AbbVie, Gilead Sciences, and Pfizer.Keith Speights(AbbVie):There's so much to like about AbbVie's dividend that it's hard to know where to begin. But I'll start with its attractive yield of 4.2%. What's even better, though, is that AbbVie is a Dividend Aristocrat-- an elite group of S&P 500members that have increased their dividends for at least 25 consecutive years.Unlike some dividend stocks, AbbVie has also delivered strong growth lately. Its shares soared 26% last year. With dividends included, the drugmaker's total return easily beat the S&P 500's performance.There are a couple of concerns for AbbVie, though. The U.S. Food and Drug Administration (FDA) recentlyplaced additional warnings on the company's JAK inhibitor Rinvoq. This could limit the sales of the drug to some extent. Also, AbbVie's top-selling drug Humira faces biosimilar rivals in the U.S. beginning in 2023. Sales are expected to decline significantly.However, AbbVie's dividend shouldn't be threatened at all. The company could also continue generating solid growth in the second half of this decade after the initial impact of Humira losing exclusivity. AbbVie has several other growth drivers, including autoimmune disease drug Skyrizi and blood cancer drug Venclexta.David Jagielski ( Gilead Sciences):Investing in a high-yielding dividend stock can be a great way to make the most of your money. But to ensure that inflation isn't chipping away at that cash flow over time, you'll also want to invest in a company that raises its dividend payments. With Gilead Sciences, investors are getting the best of both worlds -- a high yield of around 4% that has also been growing over the years.Five years ago, Gilead was paying its investors a quarterly dividend of $0.47. Today, those payments are up to $0.71, rising by 51% during that time and averaging a compound annual growth rate of 8.6%. And that already-juicy dividend can get even more mouth-watering as the company's payout ratio sits below 50%.In Gilead's latest quarterly update, sales rose 13% year over year to $7.4 billion. The company also reported net income of $2.6 billion, which equated to a per-share (diluted) profit of $2.05. And in the nine months leading up to that date, the earnings per share (EPS) topped $4.63. That's easily enough to cover the current dividend, which on an annual basis would total $2.84. And it leaves room for some generous increases as well.Now may be an optimal time to buy Gilead stock. The company typically reports its fourth-quarter earnings in early February. Gilead could announce another dividend hike then as well. Since 2015 when the company began making dividend payments, Gilead has consistently raised its payouts each subsequent year (and normally in February).With solid financials and the company likely to continue receiving a boost from its COVID-19 treatment, Veklury, it's probable that this dividend could get even juicier than it already is today.Prosper Junior Bakiny(Pfizer):When it comes to dividend stocks, high yields are great, but the ability to sustain dividend increases is even better. That's what pharma giant Pfizer provides. The company's current yield of 2.75% is well above the S&P 500's average of 1.27%. But just as important is Pfizer's very conservative cash payout ratio of 29.64%. For context, a payout ratio below the 60% range is generally considered good.This implies that Pfizer has considerable room to sustain dividend increases in large part thanks to the cash it has been generating over the past year. Pfizer's free cash flow soared by 126.1% to $29.2 billion in the trailing twelve-month period. We can attribute that primarily to Pfizer's COVID-19 vaccine, Comirnaty. This vaccine has become ablockbuster product-- and then some -- in its first year on the market.Pfizer said it would generate $36 billion from Comirnaty in the fiscal year 2021. Given recent developments surrounding the pandemic, 2022 should be another excellent year for the vaccine. Management thinks sales of Comirnaty could come in at $29 billion this year. Pfizer's coronavirus-related business alone, which includes Comirnaty and Paxlovid, a COVID-19 therapy that recently earned authorization, will generate more sales than dozens of large corporations will this year.But Pfizer has other tools at its disposal. The company's anticoagulant Eliquis, cancer medicine Xtandi, as well as its biosimilar business, are meaningfully contributing to its overall performance. Even immunosuppressant Xeljanz could return to growth this yeardespite the regulatory headwinds it encountered last year.Lastly, Pfizer's pipeline includes 29 ongoing phase 3 clinical trials. Expect new products and label expansions to strengthen an already solid lineup.And all of this at a reasonable price, too. Pfizer is trading at just 9.1 times forward earnings compared to an average price-to-earnings ratio of 13.3 for the pharma industry.In short, Pfizer provides a little bit of everything most investors look for: high growth, reasonable value, and stable income in the form of dividends. Too juicy to pass up, indeed.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9005719583,"gmtCreate":1642405954380,"gmtModify":1676533708271,"author":{"id":"3583884958321017","authorId":"3583884958321017","name":"AnaiAnai","avatar":"https://static.tigerbbs.com/8b0d0d8e20a4082ac0bc6a98756546ec","vip":1,"crmLevel":1,"crmLevelSwitch":1,"authorIdStr":"3583884958321017","idStr":"3583884958321017"},"htmlText":"mostly small player not viable yet.","listText":"mostly small player not viable yet.","text":"mostly small player not viable yet.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9005719583","repostId":1103076176,"repostType":4,"repost":{"id":"1103076176","pubTimestamp":1642404988,"share":"https://ttm.financial/m/news/1103076176?lang=&edition=fundamental","pubTime":"2022-01-17 15:36","market":"us","language":"en","title":"3 Pharma Stocks With Especially Juicy Dividends","url":"https://stock-news.laohu8.com/highlight/detail?id=1103076176","media":"Motley Fool","summary":"Key PointsAbbVie is a Dividend Aristocrat that also performed quite well over the past year.Gilead S","content":"<html><head></head><body><p>Key Points</p><ul><li>AbbVie is a Dividend Aristocrat that also performed quite well over the past year.</li><li>Gilead Sciences has increased its dividend 51% over the last five years and should keep the streak going in 2022.</li><li>Pfizer is a cash cow with a strong and stable dividend.</li></ul><p>Big pharmaceutical companies usually make big bucks. And many of them return a portion of their profits to investors in the form of dividends.</p><p>We asked three Motley Fool contributors to pick the pharma stocks that they think have especially juicy dividends. Here&#39;s why they chose <a href=\"https://laohu8.com/S/ABBV\"><b>AbbVie</b></a>, <a href=\"https://laohu8.com/S/GILD\"><b>Gilead Sciences</b></a>, and <a href=\"https://laohu8.com/S/PFE\"><b>Pfizer</b></a>.</p><p><b>Keith Speights(</b><a href=\"https://laohu8.com/S/ABBV\"><b>AbbVie</b></a><b>):</b>There&#39;s so much to like about AbbVie&#39;s dividend that it&#39;s hard to know where to begin. But I&#39;ll start with its attractive yield of 4.2%. What&#39;s even better, though, is that AbbVie is a Dividend Aristocrat-- an elite group of <b>S&amp;P 500</b>members that have increased their dividends for at least 25 consecutive years.</p><p>Unlike some dividend stocks, AbbVie has also delivered strong growth lately. Its shares soared 26% last year. With dividends included, the drugmaker&#39;s total return easily beat the S&amp;P 500&#39;s performance.</p><p>There are a couple of concerns for AbbVie, though. The U.S. Food and Drug Administration (FDA) recentlyplaced additional warnings on the company&#39;s JAK inhibitor Rinvoq. This could limit the sales of the drug to some extent. Also, AbbVie&#39;s top-selling drug Humira faces biosimilar rivals in the U.S. beginning in 2023. Sales are expected to decline significantly.</p><p>However, AbbVie&#39;s dividend shouldn&#39;t be threatened at all. The company could also continue generating solid growth in the second half of this decade after the initial impact of Humira losing exclusivity. AbbVie has several other growth drivers, including autoimmune disease drug Skyrizi and blood cancer drug Venclexta.</p><p><b>David Jagielski</b> <b>(</b> <a href=\"https://laohu8.com/S/GILD\"><b>Gilead Sciences</b></a><b>):</b>Investing in a high-yielding dividend stock can be a great way to make the most of your money. But to ensure that inflation isn&#39;t chipping away at that cash flow over time, you&#39;ll also want to invest in a company that raises its dividend payments. With Gilead Sciences, investors are getting the best of both worlds -- a high yield of around 4% that has also been growing over the years.</p><p>Five years ago, Gilead was paying its investors a quarterly dividend of $0.47. Today, those payments are up to $0.71, rising by 51% during that time and averaging a compound annual growth rate of 8.6%. And that already-juicy dividend can get even more mouth-watering as the company&#39;s payout ratio sits below 50%.</p><p>In Gilead&#39;s latest quarterly update, sales rose 13% year over year to $7.4 billion. The company also reported net income of $2.6 billion, which equated to a per-share (diluted) profit of $2.05. And in the nine months leading up to that date, the earnings per share (EPS) topped $4.63. That&#39;s easily enough to cover the current dividend, which on an annual basis would total $2.84. And it leaves room for some generous increases as well.</p><p>Now may be an optimal time to buy Gilead stock. The company typically reports its fourth-quarter earnings in early February. Gilead could announce another dividend hike then as well. Since 2015 when the company began making dividend payments, Gilead has consistently raised its payouts each subsequent year (and normally in February).</p><p>With solid financials and the company likely to continue receiving a boost from its COVID-19 treatment, Veklury, it&#39;s probable that this dividend could get even juicier than it already is today.</p><p><b>Prosper Junior Bakiny(</b><a href=\"https://laohu8.com/S/PFE\"><b>Pfizer</b></a><b>):</b>When it comes to dividend stocks, high yields are great, but the ability to sustain dividend increases is even better. That&#39;s what pharma giant Pfizer provides. The company&#39;s current yield of 2.75% is well above the S&amp;P 500&#39;s average of 1.27%. But just as important is Pfizer&#39;s very conservative cash payout ratio of 29.64%. For context, a payout ratio below the 60% range is generally considered good.</p><p>This implies that Pfizer has considerable room to sustain dividend increases in large part thanks to the cash it has been generating over the past year. Pfizer&#39;s free cash flow soared by 126.1% to $29.2 billion in the trailing twelve-month period. We can attribute that primarily to Pfizer&#39;s COVID-19 vaccine, Comirnaty. This vaccine has become ablockbuster product-- and then some -- in its first year on the market.</p><p>Pfizer said it would generate $36 billion from Comirnaty in the fiscal year 2021. Given recent developments surrounding the pandemic, 2022 should be another excellent year for the vaccine. Management thinks sales of Comirnaty could come in at $29 billion this year. Pfizer&#39;s coronavirus-related business alone, which includes Comirnaty and Paxlovid, a COVID-19 therapy that recently earned authorization, will generate more sales than dozens of large corporations will this year.</p><p>But Pfizer has other tools at its disposal. The company&#39;s anticoagulant Eliquis, cancer medicine Xtandi, as well as its biosimilar business, are meaningfully contributing to its overall performance. Even immunosuppressant Xeljanz could return to growth this yeardespite the regulatory headwinds it encountered last year.</p><p>Lastly, Pfizer&#39;s pipeline includes 29 ongoing phase 3 clinical trials. Expect new products and label expansions to strengthen an already solid lineup.</p><p>And all of this at a reasonable price, too. Pfizer is trading at just 9.1 times forward earnings compared to an average price-to-earnings ratio of 13.3 for the pharma industry.</p><p>In short, Pfizer provides a little bit of everything most investors look for: high growth, reasonable value, and stable income in the form of dividends. Too juicy to pass up, indeed.</p><p></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Pharma Stocks With Especially Juicy Dividends</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Pharma Stocks With Especially Juicy Dividends\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-17 15:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/16/3-pharma-stocks-with-especially-juicy-dividends/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Key PointsAbbVie is a Dividend Aristocrat that also performed quite well over the past year.Gilead Sciences has increased its dividend 51% over the last five years and should keep the streak going in ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/16/3-pharma-stocks-with-especially-juicy-dividends/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GILD":"吉利德科学","ABBV":"艾伯维公司","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2022/01/16/3-pharma-stocks-with-especially-juicy-dividends/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1103076176","content_text":"Key PointsAbbVie is a Dividend Aristocrat that also performed quite well over the past year.Gilead Sciences has increased its dividend 51% over the last five years and should keep the streak going in 2022.Pfizer is a cash cow with a strong and stable dividend.Big pharmaceutical companies usually make big bucks. And many of them return a portion of their profits to investors in the form of dividends.We asked three Motley Fool contributors to pick the pharma stocks that they think have especially juicy dividends. Here's why they chose AbbVie, Gilead Sciences, and Pfizer.Keith Speights(AbbVie):There's so much to like about AbbVie's dividend that it's hard to know where to begin. But I'll start with its attractive yield of 4.2%. What's even better, though, is that AbbVie is a Dividend Aristocrat-- an elite group of S&P 500members that have increased their dividends for at least 25 consecutive years.Unlike some dividend stocks, AbbVie has also delivered strong growth lately. Its shares soared 26% last year. With dividends included, the drugmaker's total return easily beat the S&P 500's performance.There are a couple of concerns for AbbVie, though. The U.S. Food and Drug Administration (FDA) recentlyplaced additional warnings on the company's JAK inhibitor Rinvoq. This could limit the sales of the drug to some extent. Also, AbbVie's top-selling drug Humira faces biosimilar rivals in the U.S. beginning in 2023. Sales are expected to decline significantly.However, AbbVie's dividend shouldn't be threatened at all. The company could also continue generating solid growth in the second half of this decade after the initial impact of Humira losing exclusivity. AbbVie has several other growth drivers, including autoimmune disease drug Skyrizi and blood cancer drug Venclexta.David Jagielski ( Gilead Sciences):Investing in a high-yielding dividend stock can be a great way to make the most of your money. But to ensure that inflation isn't chipping away at that cash flow over time, you'll also want to invest in a company that raises its dividend payments. With Gilead Sciences, investors are getting the best of both worlds -- a high yield of around 4% that has also been growing over the years.Five years ago, Gilead was paying its investors a quarterly dividend of $0.47. Today, those payments are up to $0.71, rising by 51% during that time and averaging a compound annual growth rate of 8.6%. And that already-juicy dividend can get even more mouth-watering as the company's payout ratio sits below 50%.In Gilead's latest quarterly update, sales rose 13% year over year to $7.4 billion. The company also reported net income of $2.6 billion, which equated to a per-share (diluted) profit of $2.05. And in the nine months leading up to that date, the earnings per share (EPS) topped $4.63. That's easily enough to cover the current dividend, which on an annual basis would total $2.84. And it leaves room for some generous increases as well.Now may be an optimal time to buy Gilead stock. The company typically reports its fourth-quarter earnings in early February. Gilead could announce another dividend hike then as well. Since 2015 when the company began making dividend payments, Gilead has consistently raised its payouts each subsequent year (and normally in February).With solid financials and the company likely to continue receiving a boost from its COVID-19 treatment, Veklury, it's probable that this dividend could get even juicier than it already is today.Prosper Junior Bakiny(Pfizer):When it comes to dividend stocks, high yields are great, but the ability to sustain dividend increases is even better. That's what pharma giant Pfizer provides. The company's current yield of 2.75% is well above the S&P 500's average of 1.27%. But just as important is Pfizer's very conservative cash payout ratio of 29.64%. For context, a payout ratio below the 60% range is generally considered good.This implies that Pfizer has considerable room to sustain dividend increases in large part thanks to the cash it has been generating over the past year. Pfizer's free cash flow soared by 126.1% to $29.2 billion in the trailing twelve-month period. We can attribute that primarily to Pfizer's COVID-19 vaccine, Comirnaty. This vaccine has become ablockbuster product-- and then some -- in its first year on the market.Pfizer said it would generate $36 billion from Comirnaty in the fiscal year 2021. Given recent developments surrounding the pandemic, 2022 should be another excellent year for the vaccine. Management thinks sales of Comirnaty could come in at $29 billion this year. Pfizer's coronavirus-related business alone, which includes Comirnaty and Paxlovid, a COVID-19 therapy that recently earned authorization, will generate more sales than dozens of large corporations will this year.But Pfizer has other tools at its disposal. The company's anticoagulant Eliquis, cancer medicine Xtandi, as well as its biosimilar business, are meaningfully contributing to its overall performance. Even immunosuppressant Xeljanz could return to growth this yeardespite the regulatory headwinds it encountered last year.Lastly, Pfizer's pipeline includes 29 ongoing phase 3 clinical trials. Expect new products and label expansions to strengthen an already solid lineup.And all of this at a reasonable price, too. Pfizer is trading at just 9.1 times forward earnings compared to an average price-to-earnings ratio of 13.3 for the pharma industry.In short, Pfizer provides a little bit of everything most investors look for: high growth, reasonable value, and stable income in the form of dividends. Too juicy to pass up, indeed.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9005719959,"gmtCreate":1642405589400,"gmtModify":1676533708259,"author":{"id":"4097720712211120","authorId":"4097720712211120","name":"TradeMore","avatar":"https://static.tigerbbs.com/976c10f5e71e9a3b002205015f764d44","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"4097720712211120","idStr":"4097720712211120"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9005719959","repostId":1103076176,"repostType":4,"repost":{"id":"1103076176","pubTimestamp":1642404988,"share":"https://ttm.financial/m/news/1103076176?lang=&edition=fundamental","pubTime":"2022-01-17 15:36","market":"us","language":"en","title":"3 Pharma Stocks With Especially Juicy Dividends","url":"https://stock-news.laohu8.com/highlight/detail?id=1103076176","media":"Motley Fool","summary":"Key PointsAbbVie is a Dividend Aristocrat that also performed quite well over the past year.Gilead S","content":"<html><head></head><body><p>Key Points</p><ul><li>AbbVie is a Dividend Aristocrat that also performed quite well over the past year.</li><li>Gilead Sciences has increased its dividend 51% over the last five years and should keep the streak going in 2022.</li><li>Pfizer is a cash cow with a strong and stable dividend.</li></ul><p>Big pharmaceutical companies usually make big bucks. And many of them return a portion of their profits to investors in the form of dividends.</p><p>We asked three Motley Fool contributors to pick the pharma stocks that they think have especially juicy dividends. Here&#39;s why they chose <a href=\"https://laohu8.com/S/ABBV\"><b>AbbVie</b></a>, <a href=\"https://laohu8.com/S/GILD\"><b>Gilead Sciences</b></a>, and <a href=\"https://laohu8.com/S/PFE\"><b>Pfizer</b></a>.</p><p><b>Keith Speights(</b><a href=\"https://laohu8.com/S/ABBV\"><b>AbbVie</b></a><b>):</b>There&#39;s so much to like about AbbVie&#39;s dividend that it&#39;s hard to know where to begin. But I&#39;ll start with its attractive yield of 4.2%. What&#39;s even better, though, is that AbbVie is a Dividend Aristocrat-- an elite group of <b>S&amp;P 500</b>members that have increased their dividends for at least 25 consecutive years.</p><p>Unlike some dividend stocks, AbbVie has also delivered strong growth lately. Its shares soared 26% last year. With dividends included, the drugmaker&#39;s total return easily beat the S&amp;P 500&#39;s performance.</p><p>There are a couple of concerns for AbbVie, though. The U.S. Food and Drug Administration (FDA) recentlyplaced additional warnings on the company&#39;s JAK inhibitor Rinvoq. This could limit the sales of the drug to some extent. Also, AbbVie&#39;s top-selling drug Humira faces biosimilar rivals in the U.S. beginning in 2023. Sales are expected to decline significantly.</p><p>However, AbbVie&#39;s dividend shouldn&#39;t be threatened at all. The company could also continue generating solid growth in the second half of this decade after the initial impact of Humira losing exclusivity. AbbVie has several other growth drivers, including autoimmune disease drug Skyrizi and blood cancer drug Venclexta.</p><p><b>David Jagielski</b> <b>(</b> <a href=\"https://laohu8.com/S/GILD\"><b>Gilead Sciences</b></a><b>):</b>Investing in a high-yielding dividend stock can be a great way to make the most of your money. But to ensure that inflation isn&#39;t chipping away at that cash flow over time, you&#39;ll also want to invest in a company that raises its dividend payments. With Gilead Sciences, investors are getting the best of both worlds -- a high yield of around 4% that has also been growing over the years.</p><p>Five years ago, Gilead was paying its investors a quarterly dividend of $0.47. Today, those payments are up to $0.71, rising by 51% during that time and averaging a compound annual growth rate of 8.6%. And that already-juicy dividend can get even more mouth-watering as the company&#39;s payout ratio sits below 50%.</p><p>In Gilead&#39;s latest quarterly update, sales rose 13% year over year to $7.4 billion. The company also reported net income of $2.6 billion, which equated to a per-share (diluted) profit of $2.05. And in the nine months leading up to that date, the earnings per share (EPS) topped $4.63. That&#39;s easily enough to cover the current dividend, which on an annual basis would total $2.84. And it leaves room for some generous increases as well.</p><p>Now may be an optimal time to buy Gilead stock. The company typically reports its fourth-quarter earnings in early February. Gilead could announce another dividend hike then as well. Since 2015 when the company began making dividend payments, Gilead has consistently raised its payouts each subsequent year (and normally in February).</p><p>With solid financials and the company likely to continue receiving a boost from its COVID-19 treatment, Veklury, it&#39;s probable that this dividend could get even juicier than it already is today.</p><p><b>Prosper Junior Bakiny(</b><a href=\"https://laohu8.com/S/PFE\"><b>Pfizer</b></a><b>):</b>When it comes to dividend stocks, high yields are great, but the ability to sustain dividend increases is even better. That&#39;s what pharma giant Pfizer provides. The company&#39;s current yield of 2.75% is well above the S&amp;P 500&#39;s average of 1.27%. But just as important is Pfizer&#39;s very conservative cash payout ratio of 29.64%. For context, a payout ratio below the 60% range is generally considered good.</p><p>This implies that Pfizer has considerable room to sustain dividend increases in large part thanks to the cash it has been generating over the past year. Pfizer&#39;s free cash flow soared by 126.1% to $29.2 billion in the trailing twelve-month period. We can attribute that primarily to Pfizer&#39;s COVID-19 vaccine, Comirnaty. This vaccine has become ablockbuster product-- and then some -- in its first year on the market.</p><p>Pfizer said it would generate $36 billion from Comirnaty in the fiscal year 2021. Given recent developments surrounding the pandemic, 2022 should be another excellent year for the vaccine. Management thinks sales of Comirnaty could come in at $29 billion this year. Pfizer&#39;s coronavirus-related business alone, which includes Comirnaty and Paxlovid, a COVID-19 therapy that recently earned authorization, will generate more sales than dozens of large corporations will this year.</p><p>But Pfizer has other tools at its disposal. The company&#39;s anticoagulant Eliquis, cancer medicine Xtandi, as well as its biosimilar business, are meaningfully contributing to its overall performance. Even immunosuppressant Xeljanz could return to growth this yeardespite the regulatory headwinds it encountered last year.</p><p>Lastly, Pfizer&#39;s pipeline includes 29 ongoing phase 3 clinical trials. Expect new products and label expansions to strengthen an already solid lineup.</p><p>And all of this at a reasonable price, too. Pfizer is trading at just 9.1 times forward earnings compared to an average price-to-earnings ratio of 13.3 for the pharma industry.</p><p>In short, Pfizer provides a little bit of everything most investors look for: high growth, reasonable value, and stable income in the form of dividends. Too juicy to pass up, indeed.</p><p></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Pharma Stocks With Especially Juicy Dividends</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Pharma Stocks With Especially Juicy Dividends\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-17 15:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/16/3-pharma-stocks-with-especially-juicy-dividends/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Key PointsAbbVie is a Dividend Aristocrat that also performed quite well over the past year.Gilead Sciences has increased its dividend 51% over the last five years and should keep the streak going in ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/16/3-pharma-stocks-with-especially-juicy-dividends/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GILD":"吉利德科学","ABBV":"艾伯维公司","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2022/01/16/3-pharma-stocks-with-especially-juicy-dividends/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1103076176","content_text":"Key PointsAbbVie is a Dividend Aristocrat that also performed quite well over the past year.Gilead Sciences has increased its dividend 51% over the last five years and should keep the streak going in 2022.Pfizer is a cash cow with a strong and stable dividend.Big pharmaceutical companies usually make big bucks. And many of them return a portion of their profits to investors in the form of dividends.We asked three Motley Fool contributors to pick the pharma stocks that they think have especially juicy dividends. Here's why they chose AbbVie, Gilead Sciences, and Pfizer.Keith Speights(AbbVie):There's so much to like about AbbVie's dividend that it's hard to know where to begin. But I'll start with its attractive yield of 4.2%. What's even better, though, is that AbbVie is a Dividend Aristocrat-- an elite group of S&P 500members that have increased their dividends for at least 25 consecutive years.Unlike some dividend stocks, AbbVie has also delivered strong growth lately. Its shares soared 26% last year. With dividends included, the drugmaker's total return easily beat the S&P 500's performance.There are a couple of concerns for AbbVie, though. The U.S. Food and Drug Administration (FDA) recentlyplaced additional warnings on the company's JAK inhibitor Rinvoq. This could limit the sales of the drug to some extent. Also, AbbVie's top-selling drug Humira faces biosimilar rivals in the U.S. beginning in 2023. Sales are expected to decline significantly.However, AbbVie's dividend shouldn't be threatened at all. The company could also continue generating solid growth in the second half of this decade after the initial impact of Humira losing exclusivity. AbbVie has several other growth drivers, including autoimmune disease drug Skyrizi and blood cancer drug Venclexta.David Jagielski ( Gilead Sciences):Investing in a high-yielding dividend stock can be a great way to make the most of your money. But to ensure that inflation isn't chipping away at that cash flow over time, you'll also want to invest in a company that raises its dividend payments. With Gilead Sciences, investors are getting the best of both worlds -- a high yield of around 4% that has also been growing over the years.Five years ago, Gilead was paying its investors a quarterly dividend of $0.47. Today, those payments are up to $0.71, rising by 51% during that time and averaging a compound annual growth rate of 8.6%. And that already-juicy dividend can get even more mouth-watering as the company's payout ratio sits below 50%.In Gilead's latest quarterly update, sales rose 13% year over year to $7.4 billion. The company also reported net income of $2.6 billion, which equated to a per-share (diluted) profit of $2.05. And in the nine months leading up to that date, the earnings per share (EPS) topped $4.63. That's easily enough to cover the current dividend, which on an annual basis would total $2.84. And it leaves room for some generous increases as well.Now may be an optimal time to buy Gilead stock. The company typically reports its fourth-quarter earnings in early February. Gilead could announce another dividend hike then as well. Since 2015 when the company began making dividend payments, Gilead has consistently raised its payouts each subsequent year (and normally in February).With solid financials and the company likely to continue receiving a boost from its COVID-19 treatment, Veklury, it's probable that this dividend could get even juicier than it already is today.Prosper Junior Bakiny(Pfizer):When it comes to dividend stocks, high yields are great, but the ability to sustain dividend increases is even better. That's what pharma giant Pfizer provides. The company's current yield of 2.75% is well above the S&P 500's average of 1.27%. But just as important is Pfizer's very conservative cash payout ratio of 29.64%. For context, a payout ratio below the 60% range is generally considered good.This implies that Pfizer has considerable room to sustain dividend increases in large part thanks to the cash it has been generating over the past year. Pfizer's free cash flow soared by 126.1% to $29.2 billion in the trailing twelve-month period. We can attribute that primarily to Pfizer's COVID-19 vaccine, Comirnaty. This vaccine has become ablockbuster product-- and then some -- in its first year on the market.Pfizer said it would generate $36 billion from Comirnaty in the fiscal year 2021. Given recent developments surrounding the pandemic, 2022 should be another excellent year for the vaccine. Management thinks sales of Comirnaty could come in at $29 billion this year. Pfizer's coronavirus-related business alone, which includes Comirnaty and Paxlovid, a COVID-19 therapy that recently earned authorization, will generate more sales than dozens of large corporations will this year.But Pfizer has other tools at its disposal. The company's anticoagulant Eliquis, cancer medicine Xtandi, as well as its biosimilar business, are meaningfully contributing to its overall performance. Even immunosuppressant Xeljanz could return to growth this yeardespite the regulatory headwinds it encountered last year.Lastly, Pfizer's pipeline includes 29 ongoing phase 3 clinical trials. Expect new products and label expansions to strengthen an already solid lineup.And all of this at a reasonable price, too. Pfizer is trading at just 9.1 times forward earnings compared to an average price-to-earnings ratio of 13.3 for the pharma industry.In short, Pfizer provides a little bit of everything most investors look for: high growth, reasonable value, and stable income in the form of dividends. Too juicy to pass up, indeed.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":229,"commentSize":16,"repostSize":0,"favoriteSize":3,"likeStatus":false,"favoriteStatus":false}}